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ABSTRACT
Protein-protein interactions are central to most biological processes. Although in
the field of drug discovery there is a great interest in targeting protein-protein
interactions, the discovery and development of small-molecules, which effect these
interactions has been challenging. The purpose of this project is to determine if in situ
click chemistry is a practical approach towards testing whether Bcl-XL is capable of
assembling it’s own inhibitory compounds.
Abbott laboratories developed compound ABT-737, which binds with high
affinity (Ki ≤ 1 nM) to the binding sites of Bcl-XL.36 Based on ABT-737, two acetylene
anchor molecules AM3 and AM4 have been synthesized. These anchor molecules are
distinguished by the reactivity of the their carbon-carbon triple bond. Compound AM3
contains an electron withdrawing carbonyl in the α-position to the acetylene resulting in
an activating effect towards the [1,3]-dipolar cycloaddition compared to compound AM4.
To determine the reactivity of the activated system, 1H-NMR kinetic studies were
performed to compare the relative rates of these two systems by reacting model alkynes
1,2,3, and 4 with azide AZ7. It was shown that the activated systems, 1 and 3, produce
triazoles in an accelerated rate compared to the unactivated systems 2 and 3.
To test for the self-assembly of inhibitory triazoles, the acetylenes AM3 and AM4
were incubated with Bcl-XL and 14 azide building blocks (AZ1-AZ12) for 12 hours at
xi
37°C. Subjecting these mixtures to LC/MS-SIM led to the discovery of two hit
compounds, 35 and 36, of which 35 has been chemically synthesized confirming the hit.
Future work includes the synthesis of all hit compounds. Since hit triazoles can be
syn or anti, both need to be synthesized for each hit to investigate which regioisomer Bcl-
XL generates. Tests to confirm if hit compounds are actually modulating Bcl-XL activity
will be done using conventional bio-assays. This will validate that Bcl-XL is capable of
assembling its own inhibitor via the in situ click chemistry approach to drug discovery.
1Chapter One: Introduction
1.1 Introduction to Drug Discovery
Drug discovery today most often begins with the identification of a possible
biological target, which is a protein that is known to be the major contributor to a disease.
After a target has been discovered, it is then analyzed and validated to ensure that
modulation of its activity by a drug enhances the therapeutic effects. Traditionally, the
compounds that are likely to interact with the target protein are then synthesized, one by
one, and tested for activity via high-throughput screening (HTS). When comparing the
number of library members screened to the number of leads, the hit rates are usually
low.1,2 The few lead compounds are then structurally optimized to increase the biological
activity. In the last decade, the traditional way of lead discovery approaches has seen
improvements in methods for producing, handling, and screening large libraries of
compounds.3Although improvements are in place there are still challenges of synthesis
and purification, which are labor intensive and rather difficult. A recent study showed
that the U.S. biomedical research funding rose from $48 to $94 billion over ten years
starting in the early nineties. However, the number of drug candidates submitted to the
FDA has decreased in comparison to the increase in investment. 3 Within a typical
combinatorial library, over 99% of the compounds are inactive, therefore methods for
producing only the compounds showing biological activity are highly desired.4
Traditionally, lead-discovery has been aimed at preparing and screening large
libraries of compounds in the molecular weight range of 250-600 Da and HTS hits
commonly display affinities to the target protein in the low µM to high nM range
corresponding to 6.8-9.5 kcal/mol of binding energy.2,5,6 Commonly, the large libraries of
compounds fall short of probing the potential chemical “diversity space”. In the last
years, various lead discovery approaches have been studied, in which libraries of small
2molecules (fragments) are screened for activity. Subsequently, the hit fragments are then
converted into leads by merging, linking, and building additional fragments onto them.5
These fragment based approaches allow for a more through sampling of the “diversity
space” than traditional HTS by testing N2 possibilities with N+N combinations.
Theoretically, a collection of 104 fragments can probe a chemical diversity space of 108
molecules.7
Fragment-based lead discovery entails the synthesis of libraries of lower
molecular weight compounds compared to that of traditional combinational chemistry
and parallel synthesis. These compound libraries contain molecules in the molecular
weight of 120-250 Da, have less functionality, and are typically weak inhibitors (µM-
mM). Fragments are initially selected due to their ability to bind to the protein target or to
inhibit the protein in a functional assay. Fragments with relevant binding properties are
identified and expanded or combined to create new lead compounds for further drug
discovery efforts.7
Techniques for screening fragment-based libraries can be divided into two
categories. The first entails detecting fragments and combining them by conventional
ways. Several methods of detection include functional assay screening, nuclear magnetic
resonance (NMR), X-ray crystallography, and mass spectrometry (MS).5 The second
category of fragment based library screening includes methods in which the protein target
is directly involved in the synthesis of their potent inhibitor. Methods in this category
include dynamic combinatorial chemistry and kinetically controlled target-guided
synthesis (TGS).
31.2 Fragment-Based Screening
1.2.1 Non-Enzyme Templated
1.2.1.1 Functional Assay Screening
Functional assay screening differentiates the biological mediated reaction into
several steps to obtain the hit compounds. First the libraries of building blocks are
screened with the protein to determine which bind with a higher affinity. Next, those that
bind with the highest affinity are then combined through conventional synthetic methods.
Finally, the newly synthesized library of bidentant molecules is then screened with the
protein using the same functional assay.
Generally, fragments bind to the target with low affinity (mM range) and they are
rather difficult to detect in traditional HTS assays. One way to overcome this issue is to
increase the concentrations of the fragments for the assay. The Ellman group screened a
library of fragments at 1mM concentration in a functional assay to detect inhibitors for
the important oncogenic protein kinase c-Src. They were able to detect different
fragments with inhibitory effects and synthetically linked them together to produce larger
bidentant compounds. This newly synthesized library was then re-screened to identify
inhibitors of c-Src in the nanomolar range.8 There are several advantages of the functional
screening method because the fragments are smaller. Also since fewer molecules are
screened, there is less synthesis and characterization required compared to the traditional
HTS. Prior knowledge of the protein structure, mechanism of action, or other inhibitory
leads is not necessary required for this method.
41.2.1.2 NMR-Screening
One way to identify the binding properties of the fragments is by screening the
libraries by NMR. This method is also called SAR-by-NMR, since quite often the
structure-activity relationships can be determined. This method gives structure-
determination of the fragments that bind to the active site of the protein. SAR-by-NMR is
done by screening the fragment library with 15N-labeled biological target. Prior to any
screening, the assignment of the amino acid backbone of the peptide must be determined,
which takes a significant amount of time. The hit is detected by interpreting the spectra of
the heteronuclear single quantum correlation (HSQC) experiment for changes in the
amide chemical shifts at the binding site, once the compound binds to the labeled
protein.5 Therefore, SAR-by-NMR can detect fragments that bind with low affinity to the
target, thus giving valuable information of where within the binding site the fragment has
bound. This facilitates and accelerates structure-guided synthesis of inhibitory
compounds consisting of various fragments.2 This method is limited by compound
solubility and the ability of the proteins to withstand being subjected to NMR
techniques.7 Other drawbacks include access to a high-field NMR spectrometer,
significant amounts of 15N-labeled protein, and the size of the protein (which can not be
too large).5
1.2.1.3 X-ray Crystallography Screening
Like NMR, x-ray crystallography can detect fragments that bind with weak
affinity and aid the optimization of hit compounds by providing a structural
understanding about the binding site of the protein.  Once an X-ray of the bound fragment
5with the protein is obtained, three-dimensional-structure guided optimization can begin.
Solving crystal structures becomes a relatively high-throughput screening method due to
advancements in robotics, X-ray technology, and computing power. 5 Although screening
using X-ray has become high-throughput (500-1000 compounds per screen) it is
significantly less high-throughput than other methods such as the standard high
concentration functional bioassays (10-50K) and NMR (1-10K). 2
1.2.1.4 Mass Spectrometry Screening
Ibis Therapeutics has developed a detection method to screen fragment libraries
of low affinity compounds (millimolar range) which bind to the active site of bacterial
23S ribosomal RNA (rRNA) using electrospray ionization mass spectrometery (ESI-
MS).9 This technique allows for the identification of hit compounds due to the detection
of the [M+H]+, [M+NH4] +, [M-H] +, and [M+Na] + ions. This method is high-throughput
by means of screening up to 1-10K compounds per screen.
1.2.2 Enzyme Templated Fragment-Based Screening
1.2.2.1 Introduction to Target-Guided Synthesis
Although there has been a recent increase of fragment-based lead discovery
methods, one, which is promising to deviate from the conventional lead identification
process, is target-guided synthesis. This method of lead discovery deviates from
traditional lead-discovery due to the fact that the preparation and screening of the ligand
against a particular target is combined into one step, as the target itself chooses the lead
compound. Thus, the biological target, a protein or DNA fragment, is actively involved in
synthesizing it’s own inhibitory molecules. The biological target is incubated with a
small library of low-molecular weight building blocks and when the target holds the two
with the highest affinity in the correct alignment, the covalent bond formation is
accelerated creating the inhibitory bidentant ligand. Hit identification can be as simple as
6screening the mixture to determine whether a given combination of building blocks have
produced a product. This relatively new methodology of lead discovery has the potential
to create a shortcut in the traditional drug discovery methods by combining synthesis and
screening of libraries of low-molecular weight compounds in a single step.10
Target-guided synthesis can be divided into three different approaches: (1)
dynamic combinatorial chemistry; (2) catalyst-supported target-accelerated assembly;
and (3) kinetically controlled target-guided synthesis, which are described below.
1.2.2.2 Dynamic Combinatorial Chemistry
 Dynamic combinatorial chemistry (DCC) uses the target protein’s self-assembly
processes to create libraries of chemical compounds. DCC takes advantage of the use of
reversible reactions, covalent or non-covalent, by generating a random library of divalent
molecules that are in dynamic equilibrium.11 Addition of a target protein or receptor
creates a driving force shifting the equilibrium towards the library members showing the
highest affinity.12 Thus, DCC allows for the target driven amplification of the active
constituent(s) of the entire library, hence performing a self-screening process in which
the high affinity products are expressed and retrieved from the library.12
The processes of DCC approach include: (1) preparation of a variety of building
blocks, which can reversibly react; (2) introducing a template which will result in an
amplification of the best binder and (3) isolation or re-synthesis of the best inhibitor(s).13
The selection of the building blocks must oblige to some requirements including the
ability to cover as completely as possible the geometrical and functional space of the
target sites, and reversibility of the linkage between the building blocks.12 Common non-
covalent exchanges between building blocks include hydrogen bonding and metal-ligand
coordination. Although these interactions are usually fast and proceed under mild
conditions, the isolation of the amplified product(s) is problematic due to the labile
connections between the building blocks.13 The use of covalent reactions can help reduce
the associated problems. Common reactions used in DCC include trans-esterification,14
olefin metathesis,14 and disulfide exchange.13
7Huc and Lehn showed that bCAII is able to synthesize it’s own inhibitory
compounds by reversibly sampling a variety of amine and aldehyde building blocks
which form imines through condensation reactions. This reversible reaction takes place in
or near physiological conditions and allows the system to equilibrate in the presence of
the target protein resulting in the best binding inhibitor. Once the imines are formed, they
can be irreversibly reduced by hydride reduction using NaBH3CN which “freezes” the
equilibrium generating stable amine compounds. This allows for the isolation and
analysis of the final equilibrated mixture.15
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Figure 1.1 Dynamic Combinatorial Chemistry Using bCAII. Incubation of 3 aldehydes with 4 amines
with bCAII resulted in 12 imines which were reduced with NaBH3CN to the corresponding amine.
Treatment of the incubation samples with the reducing agent is necessary in order to “freeze” the
equilibrium prior to HPLC analysis.
1.2.2.3 Catalyst-Supported Target-Accelerated Assembly
Poulsen and Bornaghi showed that by using olefin cross metathesis (Grubb’s
catalyst), bovine Carbonic Anhydrases (bCAII) can selectively bind and assemble its own
inhibitory compound from a mixture of ten olefin building blocks. (Figure 1.1) When the
aromatic sulfonamide is used as an anchor molecule, it selectively chooses the terminal
acetate to undergo cross metathesis resulting in an inhibitory olefin displaying a Ki of 4.9
8nM. Thus, by reversibly sampling a variety of building blocks, bCAII was able to bind
those with the highest affinity and create its own inhibitor.16
Vancomycin is an antibiotic that has been used for the last 40 years to treat
infections caused by Gram-positive bacteria including Staphylococcus aureus. Nicolaou
and co-workers were able to apply target-accelerated combinatorial synthesis to identify
vancomycin ligands which form dimers when incubated with the target protein, Ac-D-
Ala-D-Ala or Ac2-L-Lys-D-Ala-D-Ala. By utilizing olefin metathesis or disulfide bond
formation reactions, the enzyme was able to accelerate the formation of covalent hetero-
vancomycin dimers resulting in a vancomycin derivative with inhanced antibiotic
properties.17
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Figure 1.2 Catalyst-Supported Target-Accelerated Assembly Using bCAII.  Incubation of the
sulfonamine anchor molecule with 10 terminal alkynes with bCAII and Grubb’s catalyst, olefin metathesis
resulted in the trans olefin with a Ki = 4.9nM
1.2.2.4 Kinetically Controlled Target-Guided Synthesis
Kinetically controlled TGS has been developed in the last 10 years and it slightly
differs from DCC by allowing the protein to select its own building blocks that bind with
the highest affinity to the active site. The protein samples the various pairs of building
blocks reactants until it facilitates an irreversible reaction, which covalently connects the
pair that binds with the highest affinity.4
Although TGS is a novel methodology for the synthesis of lead compounds, it is
limited by the use of highly reactive reagents such as strong electrophiles or nucleophiles
and metal catalysts, which can sometimes harm the enzyme.  A newly developed variant
9of kinetically controlled target-guided synthesis, termed in situ click chemistry, uses
reactants that are bio-orthogonal and are thus tolerated by biological systems. As to date,
the only example of in situ click chemistry utilitized in such applications is the Huisgen
[1,3]-dipolar cycloaddition to irreversibly connect acetylene and azide building blocks all
within the enzyme’s active site. This reaction produces five-membered heterocycles,
1,2,3-triazoles, which are stable to acidic and basic hydrolysis as well as
reductive/oxidative conditions.18 Azides are perfect for click chemistry due to the
resistance to H2O, O2, and a majority of conditions used in organic chemistry.19
The thermal triazole-forming reaction produces a mixture of 1,4- and 1,5-
disubstituted regioisomers as shown in Figure 1.3. However, there are synthetic
conditions available to obtain controlled regioselectivity of the disubstituted triazoles.The
copper (I) catalyzed triazole formation produces only the 1,4-disubstituted 1,2,3-triazoles
(anti-triazole) where as the magnesium acetylides reaction20 and the ruthenium catalyzed
reaction21 result in the 1,5-disubsituted 1,2,3-triazoles (syn-triazole).
The [1,3]-dipolar cycloaddition is an excellent candidate for TGS for a variety of
reasons. Although there is a large thermodynamic driving force for the cycloaddition
(>50 kcal/mol), the thermal reaction is slow at room temperature with a high activation
barrier of approximately 25 kcal/mol. This is the feature that allows the enzyme to
selectively build the best inhibitor by sampling the various pairs of building blocks until
it binds the two with the highest affinity. These are the building blocks which potentially
overcome the energy barrier to undergo the cycloaddition. Another reason that favors this
cycloaddition is that it does not involve components that might disrupt the enzymatic
binding sites (for example no catalysts or external reagents). The reaction does not
produce any byproducts, which in theory may disrupt the protein-mediated reaction.
Once formed, the triazole can actively participate in hydrogen bonding in addition to
dipole-dipole and π-π stacking.18
10
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Figure 1.3 Synthetic Routes for Syn and Anti-Triazoles.Triazole synthesis to obtain 1:1 equimolar syn-
and anti-triazoles (neat), syn-triazoles (Gringard reagent or Ruthenium catalyst), and anti-triazoles (Copper
catalyst).
1.2.2.4.a  In situ Click Chemistry Proof of Concept - Acetylcholinesterase (AChE)
The in situ click chemistry proof of concept experiments were done using
acetylcholinesterase (AChE) as the first biological target to explore the use of the
Huisgen cycloaddition. AChE is an important enzyme in the central and peripheral
nervous system catalyzing the hydrolysis of the neurotransmitter acetylcholine.22 AChE
has two binding sites: the catalytic binding site is located at the end of a 20 Å narrow
gorge whereas the second peripheral binding site is located at the top of the gorge, near
the protein surface.10 The experiments entailed using 8 tacrine reagents (active site
ligand) of both azides and acetylenes to bind at the catalytic site as anchor molecules. An
anchor molecule is a compound that once bound to the enzyme recruits other building
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blocks of the complementary functionality to undergo the irreversible cycloaddition to
form a new, multivalent inhibitor.  In addition to the 8 anchor molecules and 50
propidium mimics again both azides and acetylenes were synthesized to bind to the
peripheral binding site.23
For concept validation, the anchor molecules (20µM) were incubated as binary
mixtures with each of the propidium mimics with eel or mouse AChE (1µM) at pH 7.4
for at least 6 hours.23 Monitoring the reaction mixture using liquid chromatography
combined with mass spectrometry in the select ion mode (LC/MS-SIM) allowed the
identification of the mass peak of the resulting product.10 LC/MS-SIM is a sensitive
detection method that has been proven to be a reliable method for the detection of the
trace amounts of hit compounds. The use of a highly sensitive instrument is essential due
to the low amount of triazole formed in the enzyme-templated reaction. This technique is
performed by comparing the SIM of the potential product from the protein-templated
reaction to that of the background reaction without the protein.  When there is an increase
of product in the in situ reaction compared to the background reaction, it can be
considered as a potential hit. This method allows for the identification of the triazoles not
only by molecular weight but also by retention times resulting in the regioisomer
assignment of the triazole formed. Of the resulting mixtures, eight in situ hits were
discovered with subpicomolar affinities and were validated by showing that no triazoles
were formed when the building blocks were incubated without AChE or when AChE was
replaced with bovine serum albumin (BSA)23 (Figure 1.4). The in situ hits were assigned
to the correct regioisomer by comparing retention times of the incubation samples with
the retention times of synthetically prepared compounds.
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Figure 1.4 In situ Click Chemistry Using AChE. Incubation of 8 tacrine with 50 propidium building
blocks with AChE (mouse or eel) resulted in 8 hit compounds showing very strong inhibitory properties.
1.2.2.4.b Carbonic Anhydrase
Carbonic Anhydrases (CA) are zinc-containing enzymes that catalyze the
dehydration of bicarbonate and the hydration of carbon dioxide.  They are central to
many biological processes including the transport of CO2/HCO3-, respiration, bone
resorption, calcification, acid secretion, and pH control.24
SH2N
O
O N3
R
SH2N
O
O
N
N
N R
bovine carbonic anhydrase II
aq. buffer pH 7.4
37oC, 40 hrs
+
(Kd = 37 nM)
44 azide 
building blocks 12 hit compounds
(Kd = 0.2 nM)
Figure 1.5 In situ Click Chemistry Using bCAII. Acetylene benzene sulfonamide and 44 azide building
blocks were incubated with bCAII resulting in 12 hit compounds.
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Inhibitors of CA coordinate to the Zn2+ ion within the active site. Para-substituted
aromatic and heteroaromatic sulfonamides have been shown to be potent inhibitory
compounds due to the ability of the sulfonamide to bind to the Zn2+ center.24,25, Mocharla
and co-workers were able to show that CA is capable of assembling inhibitors by
incubating the protein with acetylene benzene sulfonamide and a library totaling 44 azide
building blocks (Figure 1.5).27 LC/MS-SIM screening of the building blocks with bovine
CA II (bCAII) led to a total of 12 anti-triazole inhibitors (Kd = 0.2-7.1nM).28
1.2.2.4.c HIV-1 Protease
HIV-1 protease (HIV-1-Pr) is an important target for the inhibition of viral
replication thus, protease inhibitors that are effective against the wild-type and the
emerging mutants is highly desirable.18 In situ click chemistry was used to probe the
enzyme-templated reaction to determine if this method could validate new in situ hits.
Whiting and co-workers showed that incubation of an azide prepared from known
inhibitors with a library of alkynes in the presence of HIV-1 protease (SF-2) resulted in
the formation of the anti-substituted triazole (Ki=1.7nM) (Figure 1.6). Binding studies
showed that neither one of the building blocks used with HIV-1 protease showed high
affinity to the active site such as the studies with AChE and bCAII (Ki <37nM).
However, it was found that the enzyme could selectively synthesize it’s own in situ
inhibitor by saturating the active site through increasing the concentration of the reagents
(200 µM) while keeping the enzyme concentration low (15 µM) in comparison to the
reagents. The consequence of increasing the building block concentration was the
increased rate of the background triazole reaction providing an approxiately 1:1 mixture
of regioisomers. Still the enzyme templated reaction provided an enhanced regioselective
ratio of 18:1 in favor of the anti-substituted triazole. 18
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Figure 1.6 In situ Click Chemistry Using HIV-1 Protease. Neither azide and alkyne building blocks
showed high affinity to the enzyme, resulting in incubations with building block concentrations at (200
µM) and the enzyme at (15 µM). However the inhibitory anti-triazole was synthesized via the enzyme-
templated reaction.
1.3 Protein-Protein Interactions
Protein-protein interactions are central to most biological processes including
signal transduction, immune response, cell-cell recognition, cellular transcription and
translation. Since protein-protein interactions are abundant in biological processes, they
represent a large and important class of targets for human therapeutics.29 Although in the
field of drug discovery there is a great interest in targeting protein-protein interactions,
the discovery and development of small-molecules, which effect these interactions, have
been challenging. One challenge in particular is the size and shape of the protein-protein
interface which is targeted by the small molecule. Approximately 750-1,500 Å2 of
surface area is buried on either side of the interface30 which exceeds the binding area
required for small protein-protein interaction modulators (PPIM). X-ray structures of
protein-protein pairs usually do not show the small, deep gorges resembling low-
molecular-weight binding sites. 29 Another challenge is that protein-protein interfaces are
often flat lacking the potential binding sites such as small cavities or binding pockets for
small molecules.
Many protein-protein interfaces contain compact centralized regions of residues,
also termed “hot-spots”, which are crucial for the affinity of the interactions.  In crystal
structures, hot-spots are found on both surfaces of the interacting proteins and seem to be
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complementary to each other.29 The adaptive and flexible nature involved in hot spots
interfaces creates difficulties in drug discovery since there might be binding-site
conformations that can be occupied by a small molecule that is not visible in the crystal
structure.31,32,33 Thus, if protein-protein interface hot-spots are biologically designed for
binding peptides and proteins, then these hot spots might be inherently well suited for the
design of low-molecular-weight binding ligands to disrupt protein-protein interactions.29
1.4 B-Cell Lymphoma-2: Bcl-2
Apoptosis is the natural programmed cellular death used to eliminate infected or
damaged cells. The loss of control of apoptosis can lead to several abnormalities in
cellular development, tissue homeostasis, and proper defense against pathogens. Once
apoptosis becomes unregulated, it can promote serious conditions such as autoimmune
and degenerative diseases as well as cancer.34
The Bcl-2 (B-cell lymphoma) family of proteins composed of both pro-apoptotic
and anti-apoptotic members play an important role in signaling the cellular death cascade.
Members of this group contain at least one of four motifs known as Bcl-2 homology
(BH) domains (BH1 to BH4).  The proteins of the Bcl-2 family can be divided into two
groups: anti-apoptotic (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, A1) and pro-apoptotic which itself
is divided into two groups, Bax subfamily (Bax, Bak, Bok) and the BH3-only proteins
(Bad, Bid, Bim, Bik, and others).35 Although most pro-apoptotic members contain BH1
and BH2 domains, those most similar to Bcl-2 contain all four BH domains. The Bax
sub-family is very similar to Bcl-2 due to the presence of BH1, BH2, and BH3 domains
where as the BH3-only proteins possess only the BH3 domain. Thus, the BH3 binding
domain is essential for programmed cell death.34
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Figure 1.7 Protein-Protein Interactions Regulating Apoptosis
Bax and Bak (proapototic) directly mediate apoptosis and Bcl-2 family proteins (anti-
apoptotic) block the Bax/Bak activation. BH3-only proteins activate Bax/Bak mainly by
binding to anti-apoptotic Bcl-2 proteins. This frees BH3-only proteins to activate
Bak/Bax. The ratio of pro- to anti-apoptotic heterodimers is linked to cell survival. The
top cartoon shows a healthy cell undergoing the natural cell death with the ratio of
heterodimers to favor pro-apoptosis where as the bottom presents an over expression of
Bcl-2 proteins resulting in favor of cell survival (anti-apoptosis).
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After the cellular death signal, pro-apoptotic proteins Bax (located in the cytosol)
and Bak (mitochondria) form aggregates within the mitochondria outer membrane
leading to the release of cytochrome c, which triggers the mitochondrial apoptosis
cascade. On the other hand, the anti-apoptotic Bcl-2 proteins (Bcl-2 and Bcl-XL) inhibit
the release of cytochrome c, hence suppressing the apoptotic pathway by blocking
Bak/Bax activation. These anti-apoptotic proteins can form heterodimers with the pro-
apoptotic proteins of the Bcl-2 family and cell survival is correlated to the ratio of pro- to
anti-apoptotic proteins.36 (Figure 1.7)
The three-dimensional structure of Bcl-XL along with mutagenesis experiments
determined that the BH1, BH2, and BH3 domains have a large influence on the homo-
and hetero-dimerization regulating apoptosis. The BH1, BH2, and BH3 domains of BcL-
XL combine together to form an elongated hydrophobic groove in which the α helical
BH3 proteins can bind.37a,b,38 Thus, the binding of a BH3 protein to the BcL-XL cleft may
be responsible for all of the dimerization within the Bcl-2 protein family.  The role of
BcL-XL  and Bcl-2 is to form heterodimers by sequestering the pro-apoptotic BH3-only
family of proteins.39
The BH3 proteins can act as either activators or sensitizers of apoptosis. The BH3
proteins can initiate apoptosis by activating pro-apoptotic Bcl-2 proteins or inhibiting the
anti-apoptotic family proteins. The activating BH3 proteins including Bim, Bid, and
Puma can directly activate Bax and Bak resulting in the induction of apoptosis. In
contrast, other BH3 proteins such as Bad and Noxa, are called sensitizer proteins and are
unable to bind to Bax and Bak, but rather they bind to the anti-apoptotic Bcl-2 family
proteins. The result of this heterodimer interaction is that the activating proteins are then
able to directly activate Bax and Bak. The design of a PPIM to imitate the role of the
Bad-like protein-protein interaction with the BH3-binding grove of Bcl-XL is highly
attractive36 based on prior studies showing that Bcl-XL overexpression has a greater
contribution to the progression of cancer compared to Bcl-2.40
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1.4.1 Bcl-XL Inhibitor ABT-737
Researchers at Abbott laboratories screened a chemical library of low-molecular
weight compounds using SAR-by-NMR and identified two molecules to bind to the BH3-
binding domain of Bcl-XL. 4’-Fluoro-biphenyl-4-carboxylic acid (A) (dissociation
constant Kd= 0.30 mM) and 5,6,7,8-tetrahydro-naphtalen-1-ol (B) (Kd= 4.3 mM) were
shown to bind to proximal binding sites within the BH3 binding groove (Figure 1.8).
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Site 1 binder
OH
(B) Kd = 4.3mM
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(Ki = 36nM)
Structure-based 
synthesis ABT-737
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Figure 1.8 Development of ABT-737. Compounds A and B bind to Bcl-XL with Kd = 0.30 mM and 4.3
mM, respectively. Through synthetic modification and linkage, compound C was identified by structure-
based design leading to ABT-737 with (Ki ≤ 1 nM).
Site 1 sits at the bottom of a deep, well-defined hydrophobic pocket formed by
Tyr 101, Leu 108, Val 126, Phe 146 of the Bcl-XL binding cleft. This site is where two
(Asp 83 and Leu 78) of the three most significant amino acid residues responsible for the
high affinity of the BH3 domain of Bak dwell. It is this groove where the fluoric of
compound A is shown to bind.  Near the Arg 139 of Bcl-XL, the carboxyl group of A was
revealed to reside.  The tetrahydronaphthalene derivative (B) binds to site 2, considered
to be a hydrophobic region normally occupied by the third residue of Bak (Ile 85) when
bound with Bcl-XL.
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Figure 1.9 ABT-737. ABT-737 maintains high affinity (Ki ≤ 1 nM) to the binding sites of Bcl-XL, Bcl-2,
and Bcl-w.
Using SAR-by-NMR, the molecules were linked together by replacing the
biphenyl carboxyl group with an acylsulfonamide while ensuring the correct position of
the acidic proton. The tetrahydronaphthalene derivative was replaced with a 3-nitro-4-(2-
phenylthioethyl)aminophenyl group which still occupies site 2 through intramolecular
bent-back π-π stacking.  This newly designed compound (C) had an increased affinity
(inhibitory constant Ki=36 ± 1.6nM). However binding studies with 1% human serum
showed a decrease affinity by a factor of >280 due to the tight binding to HAS-III.41 The
researchers then turned to structure-based synthesis to decrease the affinity to HSA while
increasing that of Bcl-XL. By adding polar groups to the molecule to occupy the aqueous,
solvent exposed regions of Bcl-XL, which correlate to the lipophilic regions of HSA, the
molecule was able to maintain the affinity to the target protein while decreasing that to
HSA. Two alterations were made including the addition of a basic 2-dimethylaminoethyl
group attached to the 1-position of the thioethylamino group as well as replacement of the
fluorophenyl group in site 1 with a piperazine derivative. The deep groove of site 1 in
Bcl-XL contains additional space which is partially solvent exposed compared to HSA
which is more buried by nonpolar residues.36 This allowed for the attachment of a
lipophilic 4’-chlorobiphenyl group to the piperazine ring to yet increase the selective
binding to Bcl-XL while rendering the binding to HAS impossible.
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 It was shown that the newly designed compound, ABT-737, (Figure 1.9) binds
with high affinity (Ki ≤ 1 nM) to the active sites of Bcl-XL, Bcl-2, and Bcl-w. ABT-737
does not bind to the homologous proteins Bcl-B, Mcl-1, and A1 (Ki = 0.46 ± 0.11µM, > 1
µM and >  1µM, respectively.) However, in the presence of 10% human serum,
nanomolar activity was retained. Thus, ABT-737 was shown to show the same effect as
the sensitizing Bad protein when tested in purified mitochondria.
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Chapter Two: 1H-NMR Kinetic Study Comparing the Reaction Rates of
Activated and Non-activated Acetylenes in the Cycloaddition with Azides to form
Triazoles
2.1 Introduction
The goal of this project is to investigate if Bcl-XL is capable of synthesizing it’s
own multivalent inhibitory compound by in situ click chemistry. The development of
protein-protein interaction modulators was based on low-molecular weight compounds
that bind to the same binding sites as Asp 83, Leu 78, and Ile 85 residues of the
proapoptotic Bak protein. Abbott laboratories developed compound ABT-737, which
binds with high affinity (Ki ≤ 1 nM) to the binding sites of Bcl-XL.36 Thus, the project
entailed synthesis of alkyne and azide building blocks that when incubated with Bcl-XL
potentially form the triazole compounds through the [1,3]-dipolar cycloaddition. The
building blocks were designed to position the triazole within the hydrophobic pocket (site
1) of the BH3 binding groove.
In previous studies using AChE and bCAII to template the triazole formation the
building blocks bind to the active site with relatively good affinities (KD = low µM). For
TGS, it is advantageous that the enzyme is capable of holding the building blocks in a
defined geometry for sufficient time to allow the triazole formation to occur. Since the
binding sites are not as well defined as the deep binding sites of AChE, it is anticipated
that the building blocks will not bind to Bcl-XL with as high affinities and the protein-
azide-acetylene complex will most likely display a shorter lifetime compared to the in
situ click chemistry applications with AchE and bCAII. Therefore it is necessary to
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increase the reactivity of the building blocks to increase the rate of the [1,3]-dipolar
cycloaddition (Figure 2.1).
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Figure 2.1 Binding Site of Bcl-XL Occupied by ABT-737 or Azide and Alkyne Building Blocks.
Binding pocket of Bcl-XL with inhibitory compound ABT-737 as well as the azide/acetylene building
blocks occupying the same binding positions.
In experiments done by Whiting and coworkers, it has been shown that neither
one of the building blocks used with HIV-1 protease displayed good affinity to the active
site. However, the enzyme selectively synthesize its own in situ inhibitor only by
saturating the binding site by increasing the concentration of the building block reagents
(200 µM compared to 20 µM for AChE and bCAII). The enzyme concentration for HIV-
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1 was 15 µM whereas for AChE and bCAII the concentration was 1µM. Consequently,
the background reaction for HIV-1 significantly increases compared to the incubations
with AChE and bCAII making the detection of hit compounds more difficult.
Increasing the rate of the triazole formation would allow the building blocks to
react even if they reside only for a short period of time within the active site of the
protein. We hypothesize to enhance the building block reactivity by installation of an
electron-withdrawing group in the α-position to the triple bond. This suggests that the
increased rate of reaction would allow for Bcl-XL to bind low affinity building blocks
long enough to template the triazole formation.
2.2 Kinetic Studies
In order to determine if the carbonyl functionality in the α-position to the triple
bond increases the rate of the [1,3]-dipolar cycloaddition reaction the rates of reactions
for carbonyl and corresponding alkyl acetylenes were compared. Two sets of compounds
were designed to test this hypothesis. The first set of compounds consists of ester 1 and
ether 2 whereas the second set comprises amide 3 and amine 4. Our hypothesis is that the
electron-poor alkynes 1 and 3 react faster compared to the unactivated alkynes 2 and 4
(Scheme 2.1).
Compound 1 (ethyl propiolate) is commercially available and compound 2 was
synthesized from butanol using sodium hydride and propargyl bromide (Scheme 2.2).42
Compound 2 was purified by distillation. Compound 3 was prepared from N-methyl
phenethylamine, 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chlorine
(DMTMM) and propiolic acid.43 DMTMM was synthesized as reported and its 1H-NMR
matched with literature values. Compound 4 was prepared by simple alkylation of N-
methyl phenethylamine with propargyl bromide.23
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Scheme 2.1 Alkynes and Azide Used for 1H NMR Kinetic Experiments
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Alkynes 1-4 were mixed with azide AZ7 in deuterated chloroform and the relative reaction rates k1-k4 were
by 1H-NMR.
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Scheme 2.2 Synthesis of Alkynes Used for 1H NMR Kinetic Experiments
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Synthesis of alkynes 1-4 used for kinetic studies.
All of the corresponding syn- and anti-triazoles were synthesized to allow for the
identification of the products in the kinetic studies (Scheme 2.3). All of the reactions
were done using benzyl azide, AZ7, which was synthesized from benzyl chloride with
sodium azide. 44 Conditions and yields are presented in Table 2.1. Triazoles 6 and 7 were
formed through a thermal reaction. The alkyne 1 was so reactive that the products were
formed within ten minutes, resulting in a small explosion in the oven. The regioisomers 6
and 7 were assigned using NMR experiments (NOE and HMBC) to distinguish the
protons on the triazole rings. The NOE experiment (Figure 2.2) showed the proton on the
anti-triazole 7 having a strong correlation when the benzylic protons were irradiated and
vice versa. In comparison, the proton on the syn-triazole 6 did not show as strong of a
correlation when the benzylic protons were irradiated.
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Scheme 2.3 Synthesis of Syn- and Anti-Triazoles (Products of Kinetic Experiments)
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Conditions (a) neat, 80°C (equal molar syn- and anti-triazoles) (b) Copper (I) catalysis (anti-triazole) (c)
ethyl magnesium chloride reaction (syn-triazole).
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Table 2.1 Conditions and Yields for Triazoles in Scheme 2.3
Triazole
6
7
8
9
10 + 11
12
13
Condition
a
a
c
b
b
c
b
6
21
65
71
48
28
73
mixture*
Yield %
Conditions: (a) neat, 80°C (b) CuSO4•5H2O (5 mole %), L•Ascorbic
Acid (30mole %), NaHCO3 (30 mole %), tBuOH: H2O; rt, o.n.  (c)
EtMgCl,THF; reflux o.n. *mixture of syn and anti-triazoles in 1:4 ratio.
O
O
N
N
N
N
N
NO
O
δ 8.13
δ 5.92
δ 7.96
δ 5.57
Weak
NOE
Strong 
NOE
Figure 2.2 NOE Comparison for Compound 6 and 7
For compound 6 NOE experiments show a strong correlation between the anti-triazole
proton and the benzylic protons. In comparison, for the syn-triazole 7 only a weak
correlation between the syn-triazole proton and the benzylic protons were detected.
Irradiation was performed at both the benzylic and triazole protons for both
regioisomers. Values are reported in ppm.
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The syn-triazoles 8  and 12 were synthesized through the ethyl magnesium
catalyzed reaction.20 The copper (I) catalyst was used to prepare the anti-triazoles 9 and
13.45 Both reactions are selective generating pure regioisomers as products. However,
triazoles 10 and 11 were isolated as a mixture of 4:1 anti to syn and reported as such.
In order to quantify to what extent the alkynes 1-4 differ in reactivity, attempts to
determine the relative rates were undertaken. The progress of the reactions was
monitored by GC-FID or HPLC-UV. Reactions at 2M alkyne and azide concentrations
were incubated at 50°C for a period of several days. Aliquotes of the reaction mixtures
were analyzed at intervals of 24 hours. As expected, the activated alkynes 1 and 3
displayed an increased reactivity compared to the unactivated compounds 2 and 4.
Attempts to quantify the relative rates failed. Specifically, the detection and
quantification of the small amounts of triazole products in the reactions of alkynes 2 and
4 were difficult due to the detection limits of the GC-FID and HPLC-UV.
To overcome these limitations, it was decided to perform the reactions in NMR
tubes and monitor the formation of triazoles and consumption of building blocks via 1H-
NMR. Determination of the relative amounts was done by integrating the benzylic
protons of the triazole and comparing it to the benzylic protons of the starting materials.
Equal molar concentrations (2 M, 1 M, 0.5 M, and 0.25 M) of alkynes 1-4 and the
prepared benzyl azide AZ7 were mixed in deuterated chloroform and the mixtures were
kept at room temperature. The reactions were monitored over a period of five weeks.
The 1H- NMR measurements were performed daily for the first ten days followed by 48
hour intervals for an additional ten days and then every 72 hours for the remaining two
weeks. Due to the length of time of the experiments, the solvent line of the NMR tubes
was noted and refilled prior to 1H-NMR measurement. This maintained the initial
concentrations for all of the reactions. For compound 3, there were problems associated
with the solubility of triazoles 10  and 11 . Especially for the reactions at the
concentrations of 2 M, 1 M, and 0.5 M, which precipitated in the NMR tube. Hence it
was difficult to obtain precise data with these mixtures. However, the products 10 and 11
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of the reaction at 0.25 M concentration remained in solution until the studies were
complete.
The time-product profile in Figure 2.3 shows the increase in concentration (%) of
triazoles relative to time for the reaction using 2.0 M concentrations of ester 1 and ether
2 with azide AZ7. The half-life of ester 1 with AZ7 is shown to be 75 hours whereas the
half-life of ether 2 and AZ7 can not be determined. It is shown that even after 350 hours,
the triazole formation for the ether 2 and azide AZ7 is not more that 5 %. Table 2.2
shows a summary of the 1H-NMR experiments after 15 days. For each experiment the
percent of triazole is listed for the four concentrations (2 M, 1 M, 0.5 M, and 0.25 M).
Amide 3 was not detectable for 2 M, 1 M, and 0.5 M due to the insolubility of the triazole
products. The formation of triazoles for the reaction with ether 2 and amine 4 were not
detectable for at concentrations of 1 M, 0.5 M, and 0.25 M.
Figure 2.3 Time-Product Profile for 2.0 M Ester 1 and Ether 2 with Azide AZ7
The formation of triazoles for the reaction with ester 1 and  azide AZ7 is depicted
as solid circles whereas ether 2 and azide AZ7 is shown as white circles.
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Table 2.2 Percent Triazole Conversion after 15 Days
2M 1M 0.5M 0.25M
Ester 1
Ether 2
Amide 3
Amine 4
334880 65
12
4
2 n/dn/d n/d
n/dn/d n/d
n/d n/d n/d
Not detectable (n/d)
In conclusion it was shown that the activated alkynes 1 and 3 were faster in
forming the triazoles than the nonactivated alkynes 2 and 4. When comparing the 0.25 M
concentration for the two activated systems 1 and 3, the ester 1 is approximately three
times faster (33 % conversion for 1 verses 12 % for 3).
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Chapter Three: Synthesis of Alkyne Anchor Molecules and Azide Building Blocks
for the In Situ Bcl-XL Protein-Templated Cycloaddition of syn- and anti-Triazoles
3.1 Design and Synthesis of Building Block Reagents: Sulfonylacetamide
Our next experiments targeted the design and synthesis of building block reagents
and to test these for Bcl-XL -templated triazole formation as shown in Figure 2.1. Based
on the known inhibitor ABT-737 alkyne 18 was designed as an anchor molecule (Scheme
3.1) Our idea is that upon binding one of the alkynes to the protein, the protein-anchor
molecule complex will recruit azide building blocks to undergo the [1,3]-dipolar
cycloaddition resulting in triazole compounds. Based on previous experiments in
synthesizing propynamides (Scheme 2.2), it was thought that installing a
sulfonylacetamide in the same position would afford an anchor molecule 18 which is
similar to one half of ABT-737. As shown earlier, similar to the synthesis of
propynamide 3, compound 14 was reacted with commercially available propiolic acid
using DMTMM, however compound 18 could not be isolated (Scheme 3.1).43 Compound
14 was synthesized as reported and 1H NMR matched with literature values.36
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Scheme 3.1 Initial Sulfonylacetamide Attempts Using DMTMM
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Initial propynamides were synthesized using coupling conditions: DMTMM/THF, However, the
sulfonylacetamide coupling attempts using DMTMM were unsuccessful.
Owing to the failed results of the initial sulfonylacetamide coupling attempts
using DMTMM, the attention was turned to using another coupling condition. However,
attempts to couple sulfonamide 14 to propiolic acid (15)  with 1-ethyl-3-(3’-
dimethylaminopropyl)carbodiimide (EDCI) and DMAP also failed.36,43 The electron
withdrawing nature of the sulfonylacetamide moiety most likely activates the acetylene
for Michael additions. Alkynes 16 and 17 were designed to cause steric hindrance
potentially decreasing the reactivity towards Michael additions.  To prepare acid 17,
ethynyldimethyl(phenyl)silane was added to a solution of ethyl magnesium chloride
followed by passing CO2 through the mixture to  yield 17 in 58% yield.46 The synthesis of
19 and 20 were attempted with both of the EDCI and DMTMM conditions, 36,43 however,
no sulfonylacetamides 19 or 20 were obtained. The purification attempts for the
sulfonylacetamide 18-20 were done using both silica and aluminum oxide (neutral) for
the TLCs and columns.
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Scheme 3.2 Additional Sulfonylacetamide Coupling Attempts
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Further coupling conditions using bulkier acetylenes in attempts to decrease the susceptibility to Michael
addition. Conditions included EDCI/DMAP and DMTMM.
We decided to subject the mixture for high resolution mass (HRMS TOF) analysis
specifically looking for the [M+H]+ for the sulfonylacetamide 19, to which DMAP added
in a Michael reaction. This was confirmed by HRMS (TOF) m/z 542.15319 of the
product (Figure 3.1). The conclusion is that the reactivity of the sulfonylacetamides 18-20
goes beyond the synthetic challenge since such a reactive building block is not ideal for
TGS. The key to TGS is using the biological target to template the triazole formation and
if the acetylene is highly activated, such as in this case, introducing the acetylene to the
target could result in other Michael type reactions before it even reaches the targeted
protein’s binding site.
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Figure 3.1 Final Sulfonylacetamide as Michael Acceptor. Final sulfonamide product with DMAP added
in a Michael type addition. Product confirmed by HRMS (TOF) m/z 542.15319.
3.2 Design and Synthesis of Building Block Reagents: Propynamide and
Acetylenecarboxylate
Due to sulfonylacetamide activating the acetylene for Michael additions, the
designs for the alkyne anchor molecules were changed. Attention was turned to the
propynamide AM2 and ester AM3. The sulfonyl group in compound 14 would be
replaced by the methylene to afford the corresponding amine 21 or alcohol 22 which
could then be coupled to the series of acetylene acids to afford anchor molecules AM2
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and AM3. (Figure 3.2) Synthesis began with mesylating commercially available 4-fluoro-
3-nitrobenzyl alcohol with methanesulfonyl chloride to afford the corresponding 4-
fluoro-3-nitrobenzyl methanesulfonate 23 in 54% yield (Scheme 3.3). 47 Next, mesylate
23 was reacted with sodium azide to afford the benzylic azide 24 which was used without
further purification.47 In order to confirm that the azide moiety could be reduced to the
amine in the presence of the nitro group, azide 24 was reduced to amine 25 using
triphenyl phosphine.48
S
NO2H
N
S NH2
O O
14
NO2H
N
S NH2
NO2H
N
S OH
21 22
propiolic acid
S
NO2H
N
S
H
N
O O O
NO2H
N
S
H
N
O
NO2H
N
S O
O
AM2 AM3
propiolic acid propiolic acid
AM1
Figure 3.2 Modification of Acetylene Anchor Molecules. Modification of 14 to 21 and 22 to be coupled
to propiolic acid to obtain the acetylene anchor molecules AM1-AM3.
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Scheme 3.3 Synthesis of Amine 25
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O S
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O
NaN3, H2O, DMF
          rt, o.n. 
(used w/o purification)23
Initial synthesis of amine 25 to be coupled to acids bearing acetylenes.
Scheme 3.4 Attempted Synthesis of Azide 27 to be Reduced to Amine 21
F
NO2
N3
S NH2
+ S
H
N
NO2
N3
1 or 2
24 26 27
NO2H
N
S NH2
21
Reduction
Conditions for aromatic substitution: 1. DIPEA, DMSO; rt o.n.; 2. BuLi, THF; 0oC to rt o.n.
Once it was assured that the amine could be obtained, the focus shifted to the
coupling of azide 24 with amine 26 to afford azide 27 which could then in turn be
reduced to amine 21 (Scheme 3.4). 2-(Phenylthio)ethanamine) (26) was synthesized via a
nucleophilic substitution reaction between thiophenol and 2-chloroethylamine•HCL and
was purified by distillation in 52% yield.49 The initial coupling attempts of 24 and 26
were done with DIPEA as the base but no product was formed. Usage of the stronger
base BuLi did not result in product formation and therefore the synthesis was redesigned.
The idea was to use an aromatic carboxylic acid instead of the benzyl azide 24 for the
aromatic substitution with 26.
Compound 28  was obtained in 89% yield using compound 26  and the
commercially available 4-fluoro-3-nitrobenzoic acid (Scheme 3.5).50 This reaction was
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performed in a microwave reactor at 150°C for 15 min at 150W. Next the acid was
reduced to obtain the alcohol 22. Initially the reaction was performed with sodium
borohydride and borane trifluoride diethyl ether in diethylene glycol dimethyl ether
(diglyme).51 However, these conditions resulted in the reduction of the acid as well as the
aromatic nitro group. Reduction using borane in THF afforded desired product 22 in 77%
yield.52 This reduction turned out to be very sensitive and best results have been obtained
by keeping the reaction at room temperature with 12 equivalents of borane and the
reaction was carefully monitored by TLC for the appearance of the side product (nitro
reduced). Once the side product was observed, the reaction was immediately quenched
and the unreacted acid 28 was recovered.
Scheme 3.5 Initial Benzylic Amine Synthesis Attempts.
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48hrs, rt 52%
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27 21
Next, alcohol 22 was mesylated with methanesulfonyl chloride to afford the
corresponding mesylate 29 which was used without further purification.47 It was found
that the mesylate was hydrolyzing back to alcohol 22 during column chromatography.
Mesylate 29 was reacted with sodium azide to afford the benzylic azide 27 in 21%
38
yield.47 The benzylic azide 27 was then subjected to reduction conditions using triphenyl-
phosphine and 5% solution of 1N HCL. However, amine 21 could not be obtained.49
Then it was thought that the sodium azide could directly replace the alcohol
functionality in compound 22 in a mixture of carbon tetrachloride in DMF (1:4) at 90°C
followed by the addition of triphenylphosphine to afford the corresponding amine 21
(Scheme 3.6).53 However, these conditions did not afford benzylic amine 21. Next,
attempts were made by dissolving mesylate 29 in a solution of 7M ammonia in methanol
resulting in the addition of methanol obtaining compound 30 rather than the amine 21.
Since there was a replacement of the alcohol functionality, although with the O-methoxy,
it was thought to change the solvent from methanol to THF. Ammonia was bubbled into a
solution of mesylate 29 in THF at -50°C. The mixture was kept at -50°C for 45 minutes
then allowed to warm to room temperature. However, the reaction failed at forming
compound 21. Finally we attempted to synthesize amine 21 from amide 31 (Scheme 3.6).
Acid 28 was mixed with DCC and HOBT followed by the addition of ammonium
hydroxide to afford the corresponding amide 31 in 14% yield but when treated with
borane in THF, a wide range of side products were generated.54
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Scheme 3.6 Final Attempts Toward Synthesis of Amine 21
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The focus of the synthesis was then turned to ester AM3 (Figure 3.2) in place of
the amide AM2. Alcohol 22 was reacted with DCC but did not yield the corresponding
acetylene.55 Alcohol 22 was coupled to 2-butyonic acid 16 using DMTMM and N-
methylmorpholine to obtain the corresponding acetylene AM3  in 68% yield.43 In
addition, the corresponding alkyl acetylene could be synthesized to incubate with the
azide building blocks. The acetylene AM4 was prepared in 17% by alkylating alcohol 22
using propargyl bromide and sodium hydride.42
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Scheme 3.7 Synthesis of Anchor Acetylenes.
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3.3 Design and Synthesis of Building Block Reagents: Azides
With the anchor molecules AM3 and AM4 prepared, the focus was turned to
synthesize the azide building blocks. The target azides AZ1-AZ6 were synthesized via a
diazotization followed by substitution with sodium azide (Table 3.1).56 The amide linkage
of AZ4-AZ6 were synthesized by coupling acid AZ3 to the various secondary amines
using EDCI (Scheme 3.8).36
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Table 3.1 General Procedure for the Synthesis of Aromatic Azides AZ1-AZ6
NH2
R
N3
R
1. NaNO2, HCl (2M)
2. NaN3, NaOAc, Urea
    H2O, ether
    -5 to 0oC
        Compound           R                                Yield (%)
O
NO
O
AZ2
AZ4
OHO
AZ3
FAZ1
86
43
85
NO
NO
N
62
58
AZ5
AZ6 48
42
Scheme 3.8 Coupling of Acid AZ3 to Secondary Amines
N3
HO O
DMAP, EDCI
DCM
rt, Argon
N3
N O
R1
R2
+
HN
R2
R1
General coupling conditions for EDCI coupling of acid AZ3 to the
various secondary amines AZ4-AZ6.
Benzylic azides AZ7-AZ10, were prepared from the corresponding benzyl
chlorides via a SN2 reaction in the presence of sodium azide44 (Table 3.2).   AZ11 was
prepared by reacting N-(3-bromopropyl)phthalimide with tetrabutylammonium azide
(TBAAz) conditions.57 AZ12-AZ14 were prepared from the corresponding anilines using
chloroacetyl chloride followed by treatment with TBAAz to afford the desired azides
(Scheme 3.9). 57
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Table 3.2 General Procedure and Yields for Benzylic Azides AZ7-AZ10
    
        Compound           R                                Yield (%)
Cl
R
N3
R
NaN3
DMF,H2O
rt
H
F
O OH
AZ7
AZ8
AZ9
71
83
57
N3
AZ10 91
Scheme 3.9 General Procedure for Preparation of Azido Amides
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Table 3.3 Azides AZ11-AZ14 Prepared With TBAAz
         Compound           R                                Yield (%)
N
O
O
N3
H
N O
N3
H
N O
N3
H
N O
N3
AZ11
AZ12
AZ13
AZ14
50
65
71
55
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3.5 Incubations With Bcl-XL
The in situ click chemistry approach allows the enzyme to selectively build the
best inhibitor by sampling the various pairs of building blocks until it facilitates an
irreversible reaction which covalently connects the pair that binds with the highest
affinity.4 In order to determine if Bcl-XL is capable of synthesizing it’s own inhibitory
triazole, incubations of Bcl-XL with the building blocks were done followed by LC/MS-
SIM analysis of the incubation mixtures. This method is ideal because it allows for
identification of the triazoles by both molecular weight and retention time.
Incubations with Bcl-XL were performed using anchor alkynes AM3 and AM4.
The alkynes were incubated as binary mixtures with building block azides AZ1-AZ14
resulting in a total of 28 incubations. This, in theory, produces 56 triazole products since
each incubation can possibly form 2 products (syn or anti-triazole). Incubation mixtures
of acetylene and azide building blocks without Bcl-XL were also done as a control. The
incubations were done in a sealed 96-well plated which was heated to 38.5°C for 12
hours. Subsequently each sample was subjected to LC/MS-SIM analysis to determine if
the corresponding triazole products were formed in the presence of Bcl-XL.
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Figure 3.3 Binary In Situ Click Chemistry Incubations. Binary mixtures of alkyne AM3 or AM4 with
14 azide building blocks. Reagents were kept at 20 µM whereas the protein, Bcl-XL, was at 2.0 µM. After
heating the mixtures for 12 hours, the samples were analyzed by LC/MS-SIM for triazole formation.
O
O
NO2NH
S
N N
N
F
O
O
NO2NH
S
N N
N
O
NH
35 36
Figure 3.4 Triazole hits from Bcl-XL Templated Reactions.
47
Scheme 3.10 Synthesis of Hit Compound 35
N3
F +
OH
O
Neat
90oC, o.n.
99%
N
F
NN OH
O
DMTMM
N-Methylmorpholine
THF, rt,on
40%
O
O
NO2NH
S
N N
N
F
35
OH
NO2NH
S
AZ1 16 34
The incubations resulted in two potential hits, 35 and 36, which are shown in
Figure 3.4. The incubations show that Bcl-XL was in fact able to synthesize its own
inhibitory compounds as seen in Figure 3.5 and Figure 3.6. The top HP/LC-SIM trace in
Figure 3.5 shows the incubation of AM3 and AZ1 without Bcl-XL resulting in a triazole
peak (35) at 5.13 minutes with an integration area of 236 whereas the bottom trace shows
the protein-templated reaction displaying the same triazole peak at 5.13 minutes with an
integration area of 3,602. As for hit triazole 36, Figure 3.6 shows in the top trace the
incubation of AM3 and AZ12 without Bcl-XL missing any triazole peaks. However, the
bottom trace in Figure 3.6 shows the incubation of AM3 and AZ12 with Bcl-XL with a
triazole peak (36) at 5.08 minutes with the integration area of 684. The increase in peak
areas indicates that Bcl-XL is capable of synthesizing its own in situ inhibitory molecule.
Compound 34 was synthesized through a thermal reaction of AZ1 and 2-butyonic
acid (16) which afforded the anti-triazole 34 in 99% yield. Triazole 34 was then coupled
to alcohol 22 using DMTMM to afford the desired anti-triazole 35.43 NOESY was used to
confirm the regioisomer by irradiating the methyl hydrogen at 2.6 ppm and observing a
correlation at 7.6ppm. (Figure 3.7)
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Figure 3.5 In Situ Hit Identification of AM3 and AZ1 by LC/MS-SIM. Top trace: AM3 (20µM) and
AZ1 (20µM) after incubation without Bcl-XL showing a small amount triazole 35 formation with the
correct peak at 5.13 minutes ([M+H]+ 480.1). Bottom trace: AM3 (20µM) and AZ1 (20µM) after
incubation with Bcl-XL  (2.0µM) clearly showing the triazole 35 peak at 5.13 minutes.
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Figure 3.6 In Situ Hit Identification of AM3 and AZ12 by LC/MS-SIM. Top trace: AM3 (20µM) and
AZ12 (20µM) after incubation without Bcl-XL showing no distinct triazole 36 peak at 5.08 minutes. Bottom
trace: AM3 (20µM) and AZ12 (20µM) after incubation with Bcl-XL (2.0µM) showing the triazole 36 peak
at 5.08 minutes ([M+H]+ 582.6).
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Figure 3.7 NOE for Compound 34. By irradiating the hydrogen on the
methyl, it was confirmed that the regioisomer was the anti-triazole.
3.6 Conclusion
Protein-protein interactions are central to most biological processes. Although in
the field of drug discovery there is a great interest in targeting protein-protein
interactions. The discovery and development of small-molecules which effect these
interactions has been challenging. The purpose of this project is to determine if in situ
click chemistry is a practical approach towards testing whether Bcl-XL is capable of
assembling it’s own inhibitory compounds.
Abbott laboratories developed compound ABT-737 which binds with high
affinity (Ki ≤ 1 nM) to the binding sites of Bcl-XL.36 Based on ABT-737, two acetylene
anchor molecules AM3 and AM4 have been synthesized. These anchor molecules are
distinguished by the reactivity of their carbon-carbon triple bond. Compound AM3
contains an electron withdrawing carbonyl in the α-position to the acetylene resulting in
an activating effect towards the [1,3]-dipolar cycloaddition compared to compound AM4.
To determine the reactivity of the activated system, 1H-NMR kinetic studies were
performed to compare the relative rates of these two systems by reacting model alkynes
1,2,3, and 4 with azide AZ7. It was shown that the activated systems, 1 and 3, produces
triazoles in an accelerated rate compared to the unactivated systems 2 and 3.
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To test for the self-assembly of inhibitory triazoles, the acetylenes AM3 and AM4
were incubated with Bcl-XL and 14 azide building blocks (AZ1-AZ12) for 12 hours at
37°C. Subjecting these mixtures to LC/MS-SIM lead to the discovery of two hit
compounds, 35 and 36, of which one (35) has been chemically synthesized confirming
the hit.
Future work includes the synthesis of all hit compounds. Since hit triazoles can be
syn or anti, both need to be synthesized for each hit to investigate which regioisomer Bcl-
XL generates. Tests to confirm if hit compounds are actually modulating Bcl-XL activity
will be done using conventional bio-assays. This will validate that Bcl-XL is capable of
assembling its own inhibitor via the in situ click chemistry approach to drug discovery.
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Chapter Four: Experimental
General: All reactions requiring an inert atmosphere were conducted under dry argon, and
the glassware was flame dried. All common reagents and solvents were obtained from
commercial suppliers and used without any further purification unless otherwise indicated.
Solvents used for the reactions requiring an inert atmosphere were dried before their use by
passing the degassed solvent through a column of activated alumina prior to use in
reactions. Analytical TLC was performed on glass-backed plates coated with silica gel 60
with F254 indicator or EMD 100DC-Pattern aluminum-backed aluminum oxide with 60
with F254 indicator; the chromatograms were visualized under ultraviolet light and/or by
staining with a Ce/Mo or ninhydrin (amines) bromo creol green (acids) reagent and
subsequent heating. Rf values are reported on silica gel. Flash column chromatography was
carried out on EMD flash chromatography silica gel (40 µm) or on ACROS aluminium
oxide, activated, neutral (50-200 micron). Routine NMR measurements were recorded on
Bruker DPX-250 or Varian INOVA-400 spectrometers. Chemical shifts are given in ppm
relative to tetramethylsilane, which is used as an internal standard, and coupling constants
(J) are reported in Hz. 
1
H-NMR: splitting pattern abbreviations are: s, singlet; br s, broad
singlet; d, doublet; br d, broad doublet; dd, double doublet; dt, double triplet; dq, double
quartet; t, triplet; td, triple doublet; tt, triple triplet; q, quartet; quint., quintet; m, multiplet.
13
C-NMR: multiplicities were determined by DEPT, HMQC, HMBC NOE and NOESY
experiments. Standard pulse sequences were employed for the DEPT experiments. Mass
spectra was determined with a Agilent Technologies for low resolution mass spectra (LC-
MSD), and high resolution mass spectra (LC-MS-TOF), respectively; the intensities are
reported as a percentage relative to the base peak after the corresponding m/z value. ESI
Electron spray ionization technique was employed. Infrared spectra were obtained with
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Thermo Electron Corporation- Nicolet IR 100. Microwave reactions were done in a
Biotage Initiator microwave reactor.
In Situ Click Chemistry General Procedure for Binary Reagent Mixtures
(Incubation): There are two incubations for each pair of anchor molecules AM3 and
AM4  with 14 azide building blocks (AZ1-AZ14), the first set as a control (without
protein) and the second as the incubation with the protein. Acetylene AM3 (20 mM, 1
µL) was added to phosphate buffer solution (98 µL; 58 mM Na2HPO4, 17 mM NaH2PO4,
68 mM NaCl, 1 mM NaN3, pH=7.40) immediately followed by AZ1 (20 mM, 1 µL) and
were mixed and kept at 38.5 oC for 12 hours. The final concentrations were as followed:
Acetylene anchor molecules and azide building blocks: 20 µM. This set of binary
mixtures was used as the control. The incubation was done same as the control with the
exception of the addition of Bcl-XL (2 µM). The final concentrations were as followed:
Bcl-XL: (2 µM), acetylene anchor molecules and azide building blocks: 20 µM. The
measurements were performed on Agilent 1100 series LC-MSD instrument to perform
the LC/MS-SIM analysis.
1-(prop-2-ynyloxy)butane  (2)
O
The sodium hydride (60% in mineral oil) (4.37 g, 109.3 mmol, 1 eq) was washed with
hexanes (2x20mL) to remove the mineral oil. Dry THF (50 mL) was added and 1-butanol
(10.0 mL, 109.3 mmol, 1 eq) was added slowly and stirred for 10 min. The mixture was
then heated to 50°C for 15 min. and then cooled back down to room temperature. This
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mixture was then slowly added to a second flask containing propargyl bromide (80% in
toluene) (19.50 g, 131.1 mmol, 1.2 eq) dissolved in dry THF (60 mL). The resulting
mixture was refluxed overnight and reaction complete by TLC. The mixture was diluted
with  Na2CO3 (50 mL) and extracted with ether (3x100 mL) The combined organic layers
were dried with Na2SO4. The organic layer was removed under reduced vacuum. The
crude was purified by distillation (61°C) to afford the corresponding alkyne as a clear oil
in good yield (6.13 g, 54.6 mmol, 50%); 1H NMR (250 MHz, CDCl3): δ 0.93 (t, J = 7.3,
3H), 1.31-1.64 (m, 4H), 2.41 (t, J = 2.4, 1H), 3.52 (t, J = 6.5, 2H), 4.13 (d, 2H); 13C NMR
(63 MHz, CDCl3): δ 13.6 (CH3), 19.0 (CH2), 31.3 (CH2), 57.7 (CH2), 69.6 (CH2), 73.8
(CH), 79.7(C) ppm.
N-methyl-N-phenethylprop-2-ynamide  (3)
     
N O
To a solution of N-methyl phenethylamine (298 mg, 2.2 mmol, 1.1 eq) in dry THF (10
mL) propiolic acid (300 mg, 2.0 mmol, 1.0 eq) was added dropwise. After 10 min,
DMTMM (610 mg, 2.2 mmol, 1.1 eq) was added and the solution was stirred for 4.5 hrs at
rt. THF was removed under reduced vacuum and the resulting solution was dissolved in
H2O (50 mL) and extracted with ethyl acetate (4x50 mL) The combined organic layers
were dried with Na2SO4. The organic layer was removed under reduced vacuum. The
crude was purified by column chromatography on silica gel (Hx:EtOAc, 1:1) to afford the
corresponding alkyne as a clear oil with a brown tint in (330 mg, 1.76 mmol, 88%). Rf =
0.42 (Hx:EtOAc, 1:1);  1H NMR (250 MHz, CDCl3): δ 3.09 (s, 1H), 3.10 (s, 3H), 3.63 (t, J
= 7.5, 2H), 3.80 (t, J = 7.6, 2H), 7.18-7.35 (m with s at 7.260, 13H); HRMS (TOF) m/z
calcd (C12H13NO) 187.0997, found 188.1066 [M+H]
+.
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N-methyl-N-phenethylprop-2-yn-1-amine  (4)
N
To a solution of N-methyl phenethylamine (269 mg, 1.99 mmol, 3 eq) in ACN (20 mL) a
solution of K2CO3 (275 mg, 1.99 mmol, 3 eq) dissolved in H2O (2 mL) was added
followed by propargyl bromide (79.0 mg, 0.637 mmol, 1 eq). The mixture was left to stir
at rt overnight. After 18hrs an additional 1eq of propargyl bromide was added and left to
stir 3 hours. ACN was removed under reduced vacuum and redissolved in brine and
extracted with EA (3x50 mL). The organic layers were combined and washed with H2O
and dried with Na2SO4. Solvent was removed under reduced pressure. The crude was
purified by column chromatography on silica gel (Hx:EtOAc, 3:1) to afford the
corresponding alkyne as a colorless oil in (280 mg, 1.61 mmol, 87%); Rf = 0.37
(Hx:EtOAc, 3:1); 1H NMR (250 MHz, CDCl3): δ 2.23 (t, J = 2.4, 1H), 2.38 (s, 3H), 2.65-
2.72 (m, 2H), 2.75-2.82 (m, 2H), 3.41 (d, J = 2.4, 2H), 7.20-7.29 ppm (m, 5H); 13C NMR
(63 MHz, CDCl3): δ 34.0 (CH2), 41.6 (CH3), 45.4 (CH2), 57.2 (CH2), 73.1 (C), 78.2 (CH),
125.9 (CH), 128.2 (CH), 128.5 (CH), 139.9 ppm (C); HRMS (TOF) m/z calcd (C12H15N)
173.1205, found 174.1289 [M+H]+.
ethyl 1-benzyl-1H-1,2,3-triazole-5-carboxylate (6) and  ethyl 1-benzyl-1H-1,2,3-triazole-4-carboxylate  (7)
O
O
N
N
N
N
N
NO
O
6 7
Benzyl azide (563 mg, 4.23 mmol) and ethyl propiolate (415 mg, 4.23 mmol) were added
neat to a tube and sealed. The mixture was placed in the oven at 60°C. After five minutes,
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a small blast was noticed and smoke was emitted from the oven. The tube was removed
and dark crystals were noticed. The solution was dissolved in brine (100 mL) and extracted
with ethyl acetate (3x75 mL). The organic layers were combined and dried with Na2SO4
and condensed under reduced vacuum. The crude was purified by column chromatography
on silica gel (Hx:EtOAc, 4:1 to 2:1) to afford the corresponding syn- and anti-triazoles in
6%  and 21%, respectively.
Syn-substituted triazole 6: Light brown oil in (60 mg, 0.259 mmol, 6%). Rf = 0.44
(Hx:EtOAc, 2:1); 1H NMR (250 MHz, CDCl3): δ 1.35 (t, J = 7.1, 3H), 4.35 (q, J = 7.1,
2H), 5.92 (s, 2H), 7.24-7.35 (m, 5H), 8.13 ppm (s, 1H); 13C NMR (63 MHz, CDCl3): δ 14.0
(CH3), 53.2 (CH2), 61.6 (CH2), 127.6 (CH), 127.9 (CH), 128.2 (CH), 128.6 (CH), 134.8
(C), 138.0 (CH), 158.2 ppm (C=O). HRMS (TOF) m/z calcd (C12H13N3O2) 213.1008, found
232.1081 [M+H]+.
Anti- substituted triazole 7: Light orange crystal solid in (202 mg, 0.873 mmol, 21%). Rf
= 0.31 (Hx:EtOAc, 2:1); 1H NMR (250 MHz, CDCl3): δ 1.38 (t, J = 7.1, 3H), 4.4 (q, J =
7.1, 2H), 5.57 (s, 2H), 7.29-7.41 (m, 5H), 7.96 ppm (s, 1H); 13C NMR (63 MHz, CDCl3):
δ 14.0 (CH3), 54.1 (CH2), 61.1 (CH2), 126.7 (CH), 128.0 (CH), 128.8 (CH), 129.0 (CH),
133.6 (CH), 140.3 (C), 160.4 ppm (C=0). HRMS (TOF) m/z calcd (C12H13N3O2)
213.1008, found 232.1081 [M+H]+.
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N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-N-methyl-2-phenylethanamine (13)
N N
N
N
General Procedure for anti triazole: To a solution of benzyl azide (154 mg, 1.15 mmol,
1 eq) and N-methyl-N-phenethylprop-2-yn-1-amine (200 mg, 1.15 mmol, 1 eq) in a 1:1
mixture of tBuOH: H2O (2.3 mL each), CuSO4•5H2O (14.4 mg, 0.058 mmol., 5 mol %) as
a solution in 100 µL was added via a micro pipette. The copper solution was made by
adding 0.58 mM to 1 mL and using 100 µL. To a solution of L-ascorbic acid (57.8 mg,
0.35 mmole, 30 mol %) in 0.75 mL H2O sodium bicarbonate (29.0 mg, 0.35 mmol, 30 mol
%) was added. Upon addition, the solution fizzed. This mixture was added to the reaction
flask and left to stir over night at room temperature. The reaction was complete by TLC so
the reaction mixture was diluted with sat. sodium bicarbonate (100 mL) and rinsed with
dichloromethane (3x50 mL). The organic layers were combined and dried with Na2SO4
and condensed under reduced vacuum. The crude was purified by column chromatography
on silica gel (DCM:MeOH, 95:1) to afford the corresponding anti-triazole as a light brown
solid in (352 mg, 1.15 mmol, 65%); Rf = 0.25 (DCM:MeOH, 95:5); 1H NMR (250 MHz,
CDCl3): δ 2.33 (s, 3H), 2.59-2.65 (m, 2H), 2.75-2.81 (m, 2H), 3.72 (s, 2H), 5.48 (s, 2H),
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7.12-7.34 ppm (m, 11H); HRMS (TOF) m/z calcd (C19H22N4) 306.1845, found 307.1921
[M+H]+.
1-benzyl-4-(butoxymethyl)-1H-1,2,3-triazole (9)
N
N
NO
Triazole 9 was prepared from azide AZ7 (163 mg, 1.22 mmol) and acetylene 2 (137 mg,
1.22 mmol) according to the procedure for the synthesis of triazole 13. Obtained as a
brown oil in (212 mg, 0.865 mmol, 71%); Rf = 0.30 (Hx:EtOAc, 2:1); 1H NMR (250 MHz,
CDCl3): δ 0.89 (t, J = 7.3, 3H), 1.30-1.41 (m, 2H), 1.50-1.61 (m, 2H), 3.50 (t, J = 6.6, 2H),
4.59 (s, 2H),  5.52 (s, 2H), 7.25-7.43 ppm (m, 6H). ESI calculated for (C14H19ON3)
245.193, found 246.1 (M+H]+.
1-benzyl-N-methyl-N-phenethyl-1H-1,2,3-triazole-5-carboxamide (10) 
1-benzyl-N-methyl-N-phenethyl-1H-1,2,3-triazole-4-carboxamide (11)
N
N
N
N
N N
N
N
O
O
10 11
Triazoles 10 and 11 were prepared from azide AZ7 (142 mg, 1.07 mmol) and acetylene 3
(200 mg, 1.07 mmol) according to the procedure for the synthesis of triazole 13. Obtained
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as a white solid in (250 mg, 0.781 mmol, 73%) Rf = 0.33 (Hx:EtOAc, 1:1); 1H NMR (250
MHz, CDCl3): δ 2.90-3.03 (m, 4H), 3.10 (s, 3H), 3.48 (s, 3H), 3.72 (t, J = 7.7, 2H), 4.20 (t,
J = 7.5, 2H), 5.50 (s, 2H), 5.54 (s, 2H), 7.12-7.42 (m, 20H), 7.76, (s, 1H), 7.98ppm, (s,
1H); HRMS (TOF) m/z calcd (C19H20N4O) 320.1637, found 321.1722 [M+H]
+.
N-((1-benzyl-1H-1,2,3-triazol-5-yl)methyl)-N-methyl-2-phenylethanamine 12
N
N
N
N
General Procedure for syn triazole: To a flame dried flask, N-methyl-N-phenethylprop-
2-yn-1-amine (150 mg, 0.87 mmol, 1 eq) was dissolved in dry THF (0.6 mL).
ethylmagnesium chloride (0.32 mL, 0.87 mmol, 1 eq) (in 25% THF) was added dropwise.
The solution was heated to 50°C for 30 min. and cooled back down to room temperature.
Benzyl azide (115 mg, 0.87 mmol, 1 eq) was added dropwise and the mixture was refluxed
overnight. The reaction was complete by TLC and was diluted with 15mL sat. NH4CL and
extracted with ethyl acetate (3x30 mL). The organic layers were combined and dried with
Na2SO4 and condensed under reduced vacuum. The crude was purified by column
chromatography on silica gel (Hx: EtOAc, 2:1) to afford the corresponding syn triazole in
(140 mg, 0.239 mmol, 28%); Rf = 0.28 (Hx:EtOAc, 2:1); 1H NMR (250 MHz, CDCl3): δ
2.30 (s, 3H), 2.51-2.58 (m, 2H), 2.70-2.75 (m, 2H), 3.32 (s, 2H), 5.36 (s, 2H), 6.99-7.51
ppm (m, 11H). ESI m/z calculated for (C19H22N4) 306.1845, found 307.2 (M+H]
+.
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1-Benzyl-5-(butoxymethyl)-1H-1,2,3-triazole  (8)
O
N
N
N
Triazole 8 was prepared from azide AZ7 (238 mg, 1.78 mmol) and acetylene 2 (200 mg,
1.78 mmol) according to the procedure for the synthesis of triazole 12. Obtained as a light
brown oil in (212 mg, 0.86 mmol, 48%); Rf = 0.33 (Hx:EtOAc, 2:1); 1H NMR (250 MHz,
CDCl3): δ 0.89 (t, , J = 7.2, 3H), 1.23-1.4 (m, 2H), 1.45-1.57 (m, 2H), 3.24 (t, , J = 6.5,
2H), 4.37 (s, 2H), 5.62 (s, 2H), 7.17-7.38 (m, 5H), 7.62 ppm (s, 1). ESI calculated for
(C14H19ON3) 245.193, found 246.1 (M+H]
+.
3-(dimethyl(phenyl)silyl)prop-2-ynoic acid (17)
Si
OH
O
To a solution of ethyl magnesium chloride (4.23 g, 48.2 mmol) in 16 mL dry THF at 0°C,
a solution of ethynyldimethyl(phenyl)silane (4.00 g, 25.0 mmol), in 8 mL dry THF was
added and stirred for 2 hr at room temperature. The mixture was cooled to –23°C and CO2
was passed through for 30 min and left to warm to rt for 2 hours. HCL (1N, 40 mL) was
added and extracted with hexanes, dried with Na2SO4, and hexanes removed under reduced
pressure to yield bright yellow oil in (2.95 g, 14.5 mmol, 58%); Rf = 0.23 (Hx:EtOAc,
1:1); 1H NMR (250 MHz, CDCl3): δ 0.51 (s, 6H), 7.39-7.44 (m, 2H), 7.59-7.63 (m, 2H);
13C NMR (63 MHz, CDCl3): δ -1.9 (CH3), 95.0 (C), 95.1 (C), 128.1 (CH), 130.1 (CH),
133.6 (CH), 134.0 (C), 157.2 ppm (C); HRMS (TOF) m/z calcd (C11H12O2Si) 204.0607,
found 227.0517 [M+Na]+.
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(3-Nitro-4-(2-(phenylthio)ethylamino)phenyl)methanol (22)
S N
H
O2N OH
To a dry flask containing 3-nitro-4-(2-(phenylthio)ethylamino)benzoic acid (1.00 g, 3.14
mmol, 1 eq) 20mL of dry THF was added. Borane (80% in THF) (3.7 mL, 37.73 mmol, 12
eq) was added dropwise. After 4hr, THF was removed under reduced pressure and the
residue was redissolved in H2O. K2CO3 was added until neutral to pH paper. The mixture
was extracted with DCM (3x50 mL)and combined organic layers were dried with Na2SO4
and DCM was removed under reduced pressure. The crude was purified by column
chromatography on silica gel (Hx:EtOAc, 1:1) to afford the corresponding alcohol as to
yield a bright orange solid in (740 mg, 2.43 mmol, 77%); Rf = 0.43 (Hx:EtOAc, 1:1);  1H
NMR (250 MHz, CDCl3): δ 2.31(br s, 1H), 3.18 (t, J = 6.7, 2H), 3.52 (apparent q, J = 6.4,
2H), 4.55 (s, 2H), 6.72 (d, J = 8.9, 1H), 7.23-7.43 (m, 6H), 8.08 (d, J =1.6, 1H), 8.26 (t, J
=5.1, 1H); 13C NMR (63 MHz, CDCl3): δ  33.1 (CH2), 41.8 (CH2), 63.8 (CH2), 113.8
(CH), 125.1 (CH), 126.9 (CH), 128.3(C), 129.0 (CH), 130.6 (CH), 131.3(C), 134.1(CH),
135.6(CH), 144.3(C). HRMS (TOF) m/z calcd (C15H14N2O4S) 318.0674, found 336.1083
[M+NH4]
+.
4-fluoro-3-nitrobenzyl methanesulfonate (23)
F
NO2
O S
O
O
A solution of 4-fluoro-3-nitrobenzyl alcohol (1.00 g, 5.84 mmol, 1 eq) and triethylamine
(2.46 mL, 17.53 mmol, 3 eq) dissolved in ethyl ether (40 mL) was cooled to 0°C.
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Methanesulfonyl chloride (1.00 g, 8.77 mmol, 1.5 eq) was added dropwise and the
mixture was left to warm to room temperature overnight. The reaction was complete by
TLC and was diluted with brine solution (100 mL) and extracted with ethyl ether (3x100
mL). The organic layers were combined and dried with MgSO4 then condensed under
reduced vacuum. The crude was used without further purification to afford the
corresponding mesylate in (783 mg, 3.14 mmol, 53%); Rf = 0.45 (Hx:EtOAc, 1:1)
4-(azidomethyl)-1-fluoro-2-nitrobenzene (24)
F
NO2
N3
To a solution of 4-fluoro-3-nitrobenzyl methanesulfonate (750 mg, 2.81 mmol, 1eq)
dissolved in DMF (20 mL) a solution of sodium azide (650 mg, 9.99 mmol, 3.56 eq)
dissolved in H2O (4 mL) was added dropwise. The mixture was left to stir at room
temperature over night. Ethyl acetate (100 mL) was added and extracted with ice water
(3x25 mL). The organic layers were combined and dried with MgSO4 then reduced under
vacuum to yield a yellow oil in (539 mg, 2.75 mmol, 98%); Rf = 0.40 (Hx:EtOAc, 1:1);
1H NMR (250 MHz, CDCl3): δ 4.44 (s, 2H), 7.35 (d, J = 8.3, 1H), IR: broad stretch 2100
(N3).
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(4-fluoro-3-nitrophenyl)methanamine (25)
F
NO2
NH2
A solution of 4-(azidomethyl)-1-fluoro-2-nitrobenzene (94 mg, 0.479 mmol, 1 eq)
dissolved in Et2O: ethyl acetate (1:1, 1.0 mL each) was cooled to 0°C. HCL (5% 1N, 0.5
mL) was slowly added followed by addition of triphenyl phosphine (126 mg, 0.479
mmol) in portions over 15 min. The ice bath was removed and the reaction was left to stir
at room temperature overnight. The reaction was complete by TLC and the organic layer
was discarded. The aqueous layer was washed with dichloromethane (2x25 mL). The
aqueous layer was then basified with 1M NaOH to pH=8 then washed with
dichloromethane (3x50 mL). The organic layers were combined and dried with Na2SO4
and condensed under reduced vacuum. The crude was purified by column
chromatography on silica gel (Hx:EtOAc, 4:1) to afford the corresponding amine as a
bright yellow solid in (30 mg, 0.176 mmol, 37%); Rf = 0.20 (Hx:EtOAc, 4:1); 1H NMR
(250 MHz, CDCl3): Note: these values are approximates due to loss of file.  δ 4.32 (s,
2H), 6.15 (br s, 2H), 6.88 (d, 1H) 7.40 (dd, 1H), 8.10 (d,1H).
2-(phenylthio)ethanamine (26)
S NH2
To a flame dried flask, dry dichloromethane (40 mL) was added. Thiophenol (1.03 g, 10
mmol, 1 eq), 2-chloroethylamine•HCL (1.51 g, 13 mmol, 1.3 eq), and K2CO3 (4.15 g, 30
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mmol, 3 eq) were added. The mixture was stirred for 2 days and was complete by TLC.
The mixture was diluted with 50 mL H2O and extracted with dichloromethane (4x50mL)
The combined organic layers were dried with Na2SO4. The organic layer was removed
under reduced vacuum. The crude was purified by vacuum distillation (53°C) to afford the
corresponding amine as a clear oil in (804 mg, 5.25 mmol, 52%); Rf = 0.30 (DCM:MeOH,
9:1);  1H NMR (250 MHz, CDCl3): δ 1.30 (s, 2H), 2.89-3.07 (m, 4H), 7.18-7.41 (m,
5H)ppm ; 13C NMR (63 MHz, CDCl3): δ 38.0 (CH2), 40.8 (CH2), 126.1 (C), 128.8 (CH),
129.6 (CH), 135.6 (C) ppm; HRMS (TOF) m/z calcd (C8H11NS) 153.0612, found 154.0692
[M+H]+.
4-(azidomethyl)-2-nitro-N-(2-(phenylthio)ethyl)aniline (27)
S N
H
O2N N3
To a dried flask containing  3-nitro-4-(2-(phenylthio)ethylamino)benzyl methanesulfonate
(1.04 g, 5.70 mmol, 1 eq) dissolved in DMF (16 mL) a solution of sodium azide (740 mg,
11.4 mmol, 2 eq) dissolved in 3 mL H2O was added dropwise. To facilitate the sodium
azide to dissolve in the water, sonication was used.  The reaction was stirred at room
temperature overnight. The reaction mixture was diluted with H2O and was extracted with
ethyl acetate (3x100 mL). Ice was added to maintain that the DMF remained in the organic
layer. The combined organic layers were dried with Na2SO4 and the organic layer was
removed under reduced pressure. The crude was purified by column chromatography on
silica gel (Hx:EtOAc, 5:1) to afford the corresponding azide as an orange oil in (394 mg,
1.20 mmol, 21%); Rf = 0.37 (Hx:EtOAc, 5:1); 1H NMR (250 MHz, CDCl3): δ 3.15 (t, J =
6.8, 2H), 3.50 (apparent q, J = 6.4, 2H), 4.20 (s, 2H), 6.72 (d, J = 8.8, 2H), 7.20-7.39 (m,
6H), 8.07 (d, J = 2.0, 1H), 8.28 (br s, 1H); 13C NMR (63 MHz, CDCl3): δ 33.3 (CH2), 42.0
(CH2), 53.6 (CH2), 114.4  (CH), 122.7 (C), 126.9 (CH), 127.1 (CH), 129.2 (CH), 130.9
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(CH), 131.7 (CH), 134.3 (C), 136.2 (C), 144.7 (C); HRMS (TOF) m / z calcd
(C15H15N5O2S) 329.09465, found 330.10198 [M+H]
+.
3-Nitro-4-(2-(phenylthio)ethylamino)benzoic acid (28)
S N
H
O2N OH
O
To a microwave reaction vessel, 4-Fluoro-3-nitro-benzoic acid (350 mg, 1.89 mmol, 1 eq),
2-(phenylthio)ethanamine (319 mg, 2.08 mmol, 1.1 eq) were added to H2O (3 mL).
Sodium bicarbonate (548 mg, 3.97 mmol, 2.1 eq) was added and the solution fizzed and
became bright yellow. The tube was sealed and subjected to microwave at 150°C for 15
min at 150W. The solution was cooled and diluted with 1N HCL (50 mL) and extracted
with ethyl acetate (3x50 mL). The combined organic layers were dried with Na2SO4. The
organic layer was removed under reduced vacuum. The crude was purified by column
chromatography on silica gel (Hx:EtOAc, 9:1) to afford the corresponding acid as a bright
yellow crystal (1.61 mg, 5.07 mmol, 89%); Rf = 0.23 (Hx:EtOAc 9:1);  1H NMR (250
MHz, CDCl3): δ 3.13(t, J = 6.7 2H), 3.50 (apparent q, J = 6.3, 2H), 6.66 (d, J = 9.0, 1H),
7.13-7.34 (m, 6H), 7.94 (dd, J = 9.0, 1.9, 1H), 8.49 (t, J = 5.3, 1H), 8.78 (d, J =1.9, 1H);
13C NMR (63 MHz, CDCl3): δ 32.9 (CH2), 41.7 (CH2), 112.9 (CH), 118.0 (C), 126.9 (CH),
128.9 (CH), 129.4 (CH), 130.6 (CH), 131.2 (C), 133.7 (C), 136.4 (C), 146.8 (C), 166.8
(C=O); HRMS (TOF) m/z calcd (C15H14N2O4S) 318.0674, found 318.0747 [M+H]
+.
3-Nitro-4-(2-(phenylthio)ethylamino)benzyl methanesulfonate (29)
S N
H
O2N O
Ms
A solution of (3-nitro-4-(2-(phenylthio)ethylamino)phenyl)methanol (158 mg, 0.520
mmol, 1 eq) and triethylamine (0.219 mL, 1.56 mmol, 3 eq) dissolved in ethyl ether (4
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mL) was cooled to 0°C. Methanesulfonyl chloride (0.06 mL, 0.78 mmol, 1.5 eq) was
added dropwise and the mixture was left to warm to room temperature overnight. The
reaction was complete by TLC and was diluted with brine solution (50 mL) and extracted
with ethyl ether (3x50 mL). The organic layers were combined and dried with MgSO4 then
condensed under reduced vaccum to afford the corresponding mesylate which was used
without further purification.
3-Nitro-4-(2-(phenylthio)ethylamino)benzyl but-2-ynoate (AM3)
S N
H
O2N O
O
To a dried flask under argon, (3-nitro-4-(2-(phenylthio)ethylamino)phenyl)methanol (75.0
mg, 0.25 mmol, 1 eq.), 2-butynoic acid (20.7 mg, 0.25 mmol, 1 eq.), and DMTMM (203
mg, 0.73 mmol, 3 eq) were dissolved in dry THF (5 mL). N-Methylmorpholine (0.081 mL,
0.73 mmol, 3 eq) was then added dropwise. The reaction was left to stir overnight at room
temperature. The reaction was complete after 16hrs and poured into H2O (75 mL) and
extracted into ethyl acetate (4x50 mL). The combined organic layers were dried with
Na2SO4 and condensed under reduced pressure. The crude was purified by column
chromatography on silica gel (Hx:EtOAc, 4:1) to afford the corresponding alkyne as an
orange solid (68 mg, 0.212 mmol, 68%); Rf = 0.26 (Hx:EtOAc, 4:1); 1H NMR (250 MHz,
CDCl3): δ 1.98 (s, 3H), 3.18 (t,  J = 6.8, 2H), 3.54 (apparent q, J =6.8, 2H), 5.06 (s, 2H),
6.73 (d, J = 8.8, 1H), 7.28-7.43 (m, 6H), 8.19 (s, 1H), 8.30 ppm (br s, 1H); 13C NMR (63
MHz, CDCl3): δ 3.8 (CH3), 33.2 (CH2), 41.9 (CH2), 66.3 (CH2), 72.1 (C), 86.3 (C), 113.9
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(CH), 122.4 (C), 127.1 (CH), 127.7 (CH), 129.1 (CH), 130.9 (CH), 131.7 (C), 134.1 (C),
136.8 (CH), 144.8 (C), 153.4 ppm (C). HRMS (TOF) m/z calcd (C19H18N2O4S) 370.0987,
found 371.1062 [M+H]+.
2-Nitro-N-(2-(phenylthio)ethyl)-4-((prop-2-ynyloxy)methyl)aniline (AM4)
S N
H
O2N O
The sodium hydride (11.0 mg, 0.27 mmol, 1.1 eq) was washed with hexanes (2x20 mL) to
remove the mineral oil. THF (3 mL) was added followed by a solution of alcohol (75 mg,
0.25 mmol, 1 eq) in THF. After 30 min, propargyl bromide (40.3 mg, 0.27 mmol, 30 µL,
1.1 eq) was added dropwise. The reaction was left at room temperature overnight. The
reaction was neutralized with sat. NH4Cl and THF was removed under reduced vacuum.
The residue was redissolved H2O and washed with ethyl acetate (3x75 mL) and dried with
Na2SO4. The organic layer was removed under vacuum. The crude was purified by column
chromatography on silica gel (Hx:EtOAc, 4:1) to afford the corresponding alkyne as an
orange oil in (14.0 mg, 0.043 mmol, 17%); Rf = 0.45 (Hx:EtOAc, 4:1); 1H NMR (250
MHz, CDCl3): δ 2.49 (t, J = 2.4, 1H), 2.98-3.25 (m, 2H), 3.63-3.97 (m, 2H), 4.16 (d, J =
2.4, 2H), 4.49 (s, 2H), 6.84 (d, J = 8.8, 1H), 7.50-7.64 (m, 6H), 8.11-8.14 ppm (m, 2H); 13C
NMR (63 MHz, CDCl3): δ 35.8 (CH2), 54.8 (CH2), 57.2 (CH2), 70.3 (CH2), 75.0 (CH),
79.3 (C), 113.7 (CH), 123.8 (CH), 125.3 (C), 126.8 (CH), , 129.5 (CH), 131.3 (CH), 132.0
68
(C), 136.6 (CH), 142.8 (C), 144.1 ppm (C); HRMS (TOF) m/z calcd (C18H18N2O3S)
342.1038, found 360.1483 [M+NH4]+.
1-azido-4-methoxybenzene (AZ2)
N3O
General Procedure for Azide Synthesis from an Amine. Preparation of 1-azido-4-
methoxybenzene AZ2: To a solution of p-anisidine (777 mg, 6.31 mmol) in 2M
hydrochloric acid (10 mL) at 0°C, a solution of sodium nitrite (518 mg, 7.51 mmol, 1.19
eq) dissolved in distilled water (2 mL) at 0°C was added dropwise. Urea (62.9 mg, 1.01
mmol, 0.16 eq) was added, followed by the drop wise addition of a chilled solution of
sodium acetate (1.48 g, 18.1 mmol, 2.87 eq) and sodium azide (816 mg, 12.6 mmol, 1.99
eq) in distilled water (10 mL). Ether (6 mL) was added, and the solution stirred over night
at room temperature. The solution was diluted with ether (75 mL) and washed with 1M
NaOH (2x50 mL) followed by H2O (1x75 mL). The organic layer was dried with Na2SO4
and solvent removed under reduced vacuum. The crude was purified by column
chromatography on silica gel (Hx) to afford the corresponding azide as a light brown
crystal in 43% yield (402 mg, 2.70 mmol); Rf = 0.18 (Hx); 1H NMR (250 Hz, CDCl3) δ
3.80 (s, 3H), 6.93 (q, J = 9.3, 4H); 13C NMR (63 mHz) 55.5 (CH3), 115.1 (CH), 119.9 (CH)
ppm.
1-azido-4-fluorobenzene (AZ1)
N3F
The preparation of AZ1 was accomplished via the same procedure used to prepare AZ2
(3.38 g, 30.4 mmol, 58%); Rf = 0.43 (Hx); 1H NMR (250 Hz, CDCl3) δ 6.95-7.09 (m,
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4H); 13C NMR (63 mHz) 116.3 (CH), 116.7 (CH), 120.2 (CH), 120.3 (CH), 135.7 (C),
135.8 (C), 157.9 (C), 161.8 (C) ppm.
3-(4-azidophenyl)propanoic acid (AZ3)
N3
OHO
The preparation of AZ3 was accomplished via the same procedure used to prepare AZ2,
with the exception of purification by column chromatography. Purification AZ3 was
accomplished by diluting the reaction mixture with distilled water, and adding 1M NaOH
(75 mL).  The aqueous layer was extracted with ether (3x75 mL), and the ether layer was
removed to obtain crude AZ3 in the form of pale yellow crystals (3.98 g, 20.8 mmol,
86%); Rf = 0.41 (Hx:EtOAc, 1:1); 1H NMR (250 Hz, CDCl3) δ 2.67 (t, J = 7.6 Hz, 2H),
2.94 (t, J = 7.6 Hz, 2H), 6.96 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H).
3-(4-azidophenyl)-1-morpholinopropan-1-one (AZ4)
N3
NO
O
General coupling procedure for azide acid and amines. (AZ4): Under Argon, AZ3 (500
mg, 2.62 mmol) and morpholine (456 mg, 5.23 mmol, 2 eq), in the presence of EDCI (2.0
g, 10.5 mmol, 4 eq) and DMAP (320 mg, 2.62 mmol, 1 eq), were dissolved in DCM (50
70
mL) at room temperature and stirred over night.  Solution was extracted by washing with
DCM and distilled water. The crude was purified by column chromatography on silica gel
(Hx:EtOAc, 5:1) to afford the corresponding azide as orange crystals in (580 mg, 2.23
mmol, 85%); Rf = 0.47 (EtOAc); 1H NMR (250 Hz, CDCl3) δ 2.51 (t, J = 7.7, 2H), 2.87 (t,
J = 7.6, 2H), 3.29 (t, J = 4.6, 2H), 3.47 (t, J = 4.8, 2H), 3.52 (s, 4H), 6.85 (d, J = 8.4, 2H),
7.12 (d, J = 8.4, 2H); 13C NMR (63 mHz) 30.2 (CH2), 34.2 (CH2), 41.5 (CH2), 45.5 (CH2),
66.1 (CH2), 66.4 (CH2), 118.7 (CH), 129.4 (CH), 137.5 (C), 170.1 (C=O) ppm. ESI :
Calculated (C13H16O2N4) 260.29 found [M+H]+ 261.1
3-(4-azidophenyl)-N,N-dimethylpropanamide (AZ5)
N3
N
O
The preparation of AZ5 was accomplished via the same procedure used to prepare AZ4.
The reaction yielded the corresponding amide as light orange crystals in (352 mg, 1.61
mmol, 62%); Rf = 0.38 (Hx:EtOAc, 5:1); 1H NMR (250 Hz, CDCl3) δ 2.57 (t, J = 7.7 Hz,
2H), 2.93 (t with s at 2.92 ppm, J = 7.7 Hz, 8H), 6.93 (d, J = 8.5 Hz, 2H), 7.20 (d, J = 8.3
Hz, 2H); 13C NMR (63 mHz) 30.5 (CH2), 35.0 (CH2),118.9 (CH), 129.7 (CH), 137.7 (C),
138.2 (C), 171.8 (C=O) ppm. ESI : Calculated (C11H14ON4) 218.23 found [M+H]+ 219.1
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3-(4-azidophenyl)-1-(4-phenylpiperazin-1-yl)propan-1-one (AZ6)
N3
N
O
N
The preparation of AZ6 was accomplished via the same procedure used to prepare AZ4.
The reaction yielded thick, light orange crystals (848 mg, 2.53 mmol, 48%). Rf = 0.40
(Hx:EtOAc, 1:1; 1H NMR (250 Hz, CDCl3) δ 2.97 (t, J = 7.7 Hz, 2H), 3.28-3.43 (m, 6H),
3.87 (t, J = 2.6 Hz, 2H), 4.10 (t, J = 2.6 Hz, 2H), 7.21-7.29 (m, 5H), 7.53-7.64 (m, 4H);13C
NMR (63 mHz) 30.6 (CH2), 34.7 (CH2), 41.4 (CH2), 49.5 (CH2), 116.6 (CH), 119.0 (CH),
120.6 (CH), 129.1 (CH), 129.7 (CH), 137.9 (C), 150.6 (C), 170.3 (C=O). ESI : Calculated
(C18H21ON5) 335.18 found [M+H]+ 336.1.
.
Benzyl azide (5) / (AZ7)
N3
General Procedure for Azides from Chlorides: Benzyl chloride (5.0 g, 39.5 mmol) and
sodium azide (7.70 g, 119 mmol, 3 eq) in a solution of DMF (50 mL) and distilled water
(30 mL) were stirred over night at room temperature. The solution was extracted with ether
(2x100 mL) followed by H2O (1x100 mL). The organic layers were combined and dried
with Na2SO4 and solvent removed under reduced vacuum. The crude was purified by
column chromatography on silica gel (Hx) to afford the corresponding azide as a clear,
colorless oil in (3.4 g, 28.1 mmol, 71%); Rf = 0.4 (Hx); 1H NMR (250 Hz, CDCl3) δ 4.35
(s, 2H), 7.32-7.43 (m, 5H).
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1-(azidomethyl)-4-fluorobenzene (AZ8)
F
N3
To a solution of 4-fluorobenzyl chloride (1.00 g, 6.92 mmol., 1 eq) dissolved in DMSO
(0.5M, 19.83 mL) a solution of sodium azide (674 mg, 10.4 mmol., 1.5 eq) dissolved in
H2O (15 mL) was added dropwise. To facilitate the sodium azide to dissolve in the water,
sonication was used.  The reaction was stirred at 70°C overnight. The reaction mixture
was diluted with H2O (75 mL) was extracted with ethyl acetate (3x75 mL). The combined
organic layers were dried with Na2SO4 and the organic layer was removed under reduced
pressure. The crude was purified by column chromatography on silica gel (Hx) to afford
the corresponding azide as a clear oil (864 mg, 5.71 mmol, 83%); Rf = 0.30 (Hx); 1H
NMR (250 MHz, CDCl3): δ  4.32 (s, 2H), 7.08 (t, J = 8.7, 2H), 7.27-7.33 (m, 2H).
GC/MS: Calculated (C7H6N4F) 151.2 found [M]+ 151.
4-(azidomethyl)benzoic acid (AZ9)
N3
HO
O
The preparation of AZ9 was accomplished via the same procedure used to prepare AZ7.
(939 mg, 5.30 mmol, 57%); Rf = 0.47 (Hx:EtOAc, 3:2); 1H NMR (250 MHz, CDCl3): δ
4.45 (s, 2H), 7.44 (d, J = 8.1, 2H), 8.14 (d, J = 8.3, 2H); HRMS (TOF) m/z calcd
(C8H7N3O2) 177.05383, found 178.06214 [M+H]
+.
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1-(azidomethyl)naphthalene (AZ10)
N3
The preparation of AZ10 was accomplished via the same procedure used to prepare AZ7.
(2.87 g, 15.7 mmol, 91%); Rf = 0.22 (Hx:EtOAc, 3:1); 1H NMR (250 MHz, CDCl3): δ
4.78 (s, 2H), 7.42-8.06 (m, 7H).
2-(2-azidoethyl)isoindoline-1,3-dione (AZ11)
N
O
O
N3
The preparation of AZ11 was accomplished via the same procedure used to prepare AZ7.
(323 mg, 1.49 mmol, 95%); 1H NMR (250 MHz, CDCl3): δ 3.58 (t, J = 5.9, 2H), 3.90 (t,
J = 5.9, 2H), 7.71-7.88 (m, 4H); 13C NMR (63 MHz, CDCl3): δ 36.8 (CH2), 48.9 (CH2),
123.4 (2xCH), 131.8 (2xC), 134.1 (2xCH), 167.9 (2xC); HRMS (TOF) m/z calcd
(C10H8N4O2) 216.06473, found 217.07174 [M+H]+.
2-azido-N-phenylethanamide (AZ13)
H
N O
N3
General Procedure for Preparation of Azido Amides (AZ13): To a solution of analine
(500 mg, 5.37 mmol, 1.2 eq) in H2O:EA (11 mL each, 1:1) KOH (904 mg, 16.11 mmol,
3.3 eq) was added and stirred vigorously. Chloroacetyl chloride (619 mg, 4.88 mmol, 1.0
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eq) was added dropwise over a period of 5 minutes. The reaction was left to stir at room
temperature for 30 minutes. The mixture was bored into brine and extracted into ethyl
acetate (3x50 mL). The organic layers were combined and dried with Na2SO4 and
condensed under reduced vacuum. The crude was purified by column chromatography on
silica gel to afford the corresponding chloroacetanilide in (847 mg, 5.0 mmol, 94%). To a
solution of chloroacetanilide (300 mg, 1.77 mmol) in THF (1 mL) TBAAz (2M solution in
THF) (756 mg, 2.66 mmol) was added and left to stir overnight at room temperature. The
crude was purified by column chromatography on silica gel (Hx: EtOAc, 1:1) to afford the
corresponding azide in (220 mg, 1.25 mmol, 71%); 1H NMR (250 MHz, CDCl3): δ 4.16 (s,
2H), 7.13-7.56 (m, 6H), 7.98 (br s, 1H); 13C NMR (63 MHz, CDCl3): δ 52.8 (CH2), 120.0
(CH), 124.9 (CH), 129.0 (CH), 136.6 (C), 164.5 (C); HRMS (TOF) m/z calcd (C8H8N4O)
176.06981, found 177.07683 [M+H]+.
2-azido-N-(naphthalen-1-yl)ethanamide (AZ12)
H
N O
N3
The preparation of AZ12 was accomplished via the same procedure used to prepare
AZ13.  Obtained in 55% yield. 1H NMR (250 MHz, CDCl3): δ 4.32 (s, 2H), 7.45-8.03
(m, 7H), 8.54 (br s, 1H); 13C NMR (63 MHz, CDCl3): δ 53.2 (CH2), 120.1 (CH), 120.4
(CH), 125.6 (CH), 126.1 (CH), 126.2 (CH), 126.5 (CH), 128.8 (CH), 131.0 (C), 134.0
(C), 164.9 (C) ppm; HRMS (TOF) m/z calcd (C12H10N4O) 226.08546, found 227.09193
[M+H]+.
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2-azido-N-(4-isopropylphenyl)ethanamide (AZ14)
H
N O
N3
The preparation of AZ14 was accomplished via the same procedure used to prepare
AZ13. (292 mg, 1.34 mmol, 94%); 1H NMR (250 MHz, CDCl3): δ 1.27 (d, J = 6.9, 6H),
2.88-2.99 (m, 1H), 4.17 (s, 2H) 7.23-7.50 (m, 4H), 8.02 (br s, 1H); 13C NMR (63 MHz,
CDCl3): δ 23.9 (2xCH3), 33.6 (CH), 52.9 (CH2), 120.2 (CH), 126.9 (CH), 134.3 (C),
145.7 (C), 164.3 (C); HRMS (TOF) m/z calcd (C11H14N4O) 218.11676, found 219.12373
[M+H]+.
1-(4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylic acid (34)
N
F
NN OH
O
Azide AZ1 (400 mg, 2.92 mmol) and butynoic acid 16 (245 mg, 3.39 mmol) were heated
as a neat solution at 80°C overnight. The reaction was then diluted with ethyl acetate and
extracted with brine solution. The corresponding triazole was obtained as a brown solid
without any further purification in (639 mg, 2.89 mmol, 99%). Rf = 0.35 (DCM:MeOH,
9:1); 1H NMR (250 Hz, CDCl3) 2.56 (s, 3H), 7.36-7.41 (m, 2H), 7.60-7.63 (m, 2H).
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3-nitro-4-(2-(phenylthio)ethylamino)benzyl 1-(4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate (35)
O
O
NO2NH
S
N N
N
F
To a dried flask under argon, (3-nitro-4-(2-(phenylthio)ethylamino)phenyl)methanol
(0.25 mmol, 1 eq), 34 (40 mg, 0.18 mmol, 1 eq), and DMTMM (0.73 mmol, 3 eq) were
dissolved in dry THF (5 mL). N-Methylmorpholine (0.73 mmol, 3eq) was then added
dropwise. The reaction was left to stir overnight at room temperature. The reaction was
complete after 16hrs and poured into H2O (75 mL) and extracted into ethyl acetate (4x50
mL). The combined organic layers were dried with Na2SO4 and condensed under reduced
pressure. The crude was purified by column chromatography on silica gel (Hx:EtOAc,
1:1) to afford the corresponding triazole in 40% yield. Rf = 0.40 (Hx:EtOAc, 1:1); 1H
NMR (250 MHz, CDCl3): δ 1.86 (s, 3H), 3.21 (t,  J = 6.8, 2H), 3.54 (apparent q, J =6.4,
2H), 5.11 (s, 2H), 6.72 (d, J = 8.8, 1H), 7.11-7.44 (m, 9H), 8.08 (d, J =1.9, 1H), 8.34 (t, J
=4.9, 1H).
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Figure A1 1H NMR and 13C NMR of Compound 2
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Figure A2 1H NMR of Compound 3
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Figure A3 1H NMR and 13C NMR of Compound 4
85
Appendix A: (Continued)
Figure A4 1H NMR and 13C NMR of Compound 6
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Figure A5 1H NMR and 13C NMR of Compound 7
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Figure A6 1H NMR of Compound 8
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Figure A8 1H NMR of Compound 10 and 11
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Figure A10 1H NMR of Compound 13
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Figure A11 1H NMR and 13C NMR of Compound 17
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Figure A12 1H NMR and 13C NMR of Compound 22
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Figure A15 1H NMR and 13C NMR of Compound 26
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Figure A16 1H NMR and 13C NMR of Compound 27
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Figure A17 1H NMR and 13C NMR of Compound 28
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Figure A18 1H NMR and 13C NMR of Compound AM3
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Figure A19 1H NMR and 13C NMR of Compound AM4
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Figure A20 1H NMR of Compound 34
Figure A21 1H NMR of Compound 35
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Figure A22 1H NMR and 13C NMR of Compound AZ1
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Figure A23 1H NMR and 13C NMR of Compound AZ2
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Figure A24 1H NMR Compound AZ3
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Figure A25 1H NMR and 13C NMR of Compound AZ4
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Figure A26 1H NMR and 13C NMR of Compound AZ5
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Figure A27 1H NMR and 13C NMR of Compound AZ6
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Figure A28 1H NMR Compound AZ7
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Figure A29 1H NMR Compound AZ8
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Figure A31 1H NMR Compound AZ10
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Figure A32 1H NMR and 13C NMR of Compound AZ11
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Figure A33 1H NMR and 13C NMR of Compound AZ12
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Figure A34 1H NMR and 13C NMR of Compound AZ13
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Figure A35 1H NMR and 13C NMR of Compound AZ14
